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Abstract
The skin is colonized by communities of bacteria, fungi, and viruses, collectively referred to as the skin
microbiome. These microbial communities are shaped by the topology and diseases of the skin.
Dysbiosis of the cutaneous microbiome has been associated with several ailments of the skin including
atopic dermatitis, acne, rosacea, psoriasis, and chronic wounds. However, our understandings of the
processes by which these microbes initiate, maintain, or modulate skin diseases is lacking. Moreover,
previous research on the topic has largely been limited by cross-sectional study designs, neglecting the
natural dynamism of microbial communities. Here we present a comprehensive analysis of the temporal
dynamics of the skin microbiome in various diseases. In the first section, we characterize the diversity
and dynamics of both bacterial and fungal communities colonizing chronic wounds and its associations
with clinical outcomes. In a study of 100 subjects with diabetic foot ulcers, we sampled the wound
microbiota in 2-week intervals until healing, amputation of 26 weeks of follow-up. We demonstrate the
high levels of community instability in chronic wounds and expose the positive association between
wound healing community instability. We also reveal the effect of antibiotic perturbation on the
microbiota. The fungal component was found to have associations with various bacteria and clinical
outcomes. Our results should inform the design of future studies and provides evidence that microbial
dynamics may be an effective biomarker for identifying high-risk ulcers. The second section investigates
the body-site specific effects of psoriasis on the skin microbiome and how it responds to therapy. We
reveal these patterns in a study of 114 subjects, across 6 body sites, and over 112 weeks of follow-up.
The effect of psoriatic lesions was found to be mild and body-site specific. In contrast, ustekinumab
treatment was found to induce moderate shifts in microbial composition, including an increase in atypical
skin bacteria and inter-individual heterogeneity. These results suggest that the effect of psoriasis lesions
is secondary to the effect the broad effects of the immune environment. Together the work presented in
this thesis represents a significant advancement in our understanding of the microbial dynamics of the
skin and their associations with human health.
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ABSTRACT

TEMPORAL DYNAMICS OF THE SKIN MICROBIOME IN DISEASE
Michael A Loesche
Elizabeth A Grice, PhD

The skin is colonized by communities of bacteria, fungi, and viruses, collectively referred to as
the skin microbiome. These microbial communities are shaped by the topology and diseases of
the skin. Dysbiosis of the cutaneous microbiome has been associated with several ailments of the
skin including atopic dermatitis, acne, rosacea, psoriasis, and chronic wounds. However, our
understandings of the processes by which these microbes initiate, maintain, or modulate skin
diseases is lacking. Moreover, previous research on the topic has largely been limited by crosssectional study designs, neglecting the natural dynamism of microbial communities. Here we
present a comprehensive analysis of the temporal dynamics of the skin microbiome in various
diseases. In the first section, we characterize the diversity and dynamics of both bacterial and
fungal communities colonizing chronic wounds and its associations with clinical outcomes. In a
study of 100 subjects with diabetic foot ulcers, we sampled the wound microbiota in 2-week
intervals until healing, amputation of 26 weeks of follow-up. We demonstrate the high levels of
community instability in chronic wounds and expose the positive association between wound
healing community instability. We also reveal the effect of antibiotic perturbation on the
microbiota. The fungal component was found to have associations with various bacteria and
clinical outcomes. Our results should inform the design of future studies and provides evidence
that microbial dynamics may be an effective biomarker for identifying high-risk ulcers. The
v

second section investigates the body-site specific effects of psoriasis on the skin microbiome and
how it responds to therapy. We reveal these patterns in a study of 114 subjects, across 6 body
sites, and over 112 weeks of follow-up. The effect of psoriatic lesions was found to be mild and
body-site specific. In contrast, ustekinumab treatment was found to induce moderate shifts in
microbial composition, including an increase in atypical skin bacteria and inter-individual
heterogeneity. These results suggest that the effect of psoriasis lesions is secondary to the effect
the broad effects of the immune environment. Together the work presented in this thesis
represents a significant advancement in our understanding of the microbial dynamics of the skin
and their associations with human health.
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CHAPTER 1 – Introduction to the Skin Microbiome

1.1 From Microscopes to Microbiomes
It was advancements in the field of microscopy that led to the discovery of bacteria and
other microbes inhabiting our world in 1676 by Antonie van Leeuwenhoek (Dobell 1960),
ushering in an era of awe and fascination with the microscopic world that persists to this day. It
did not take long before many noticed large discrepancies between numbers of bacteria visible
under a microscope and the number of colonies they could culture on a plate. In some cases the
difference between the two was several orders of magnitude, a phenomenon known as the great
plate count anomaly (Staley & Konopka 1985). Bacteria, such as E. coli, that are easily cultured
have fueled decades of discovery in genetics, molecular biology, and modern medicine. However,
the fastidious and oligotrophic bacteria that have eluded being cultured greatly outnumber those
that have. It is now estimated that 95-99% of bacteria are not readily culturable, though focused
efforts to improve culturing surveys are changing this number (Browne et al. 2016).

It was the development of next-generation sequencing technology that facilitated the
study of entire microbial communities or microbiomes, overcoming the biases and limitations of
culturing techniques. The term microbiome refers to the community of bacteria, fungi, viruses
and other microbes occupying an ecological niche. Microbiome studies have revealed rich and
complex communities inhabiting nearly all surfaces of the environment, including the human
body (Gevers et al. 2012). They have led to significant increases in our understanding of
microbial ecology, host-microbe interactions, and microbe-microbe interactions. To manage the
massive amounts of data generated by microbiome studies, the field of microbiology has become
the recipient of a rapid infusion of bioinformatics and computational biology. The rich data sets
1

have also attracted inter-disciplinary collaborations resulting in the adoption of theories and
methodologies from many fields including ecology, multivariate statistical modeling, machinelearning, evolution, phylogenetics, and network analysis.

The study of the world’s microbiomes is still in its infancy, though rapid progress is
being made. Studies characterizing microbial communities and documenting ecological
phenomenon are being published at an ever-increasing rate. Standards for sample collection,
processing, and analysis are beginning to become formalized; and tools to manipulate the
microbiome, experimentally and medically, are being developed. After more than a century of
mechanistic and hypothesis driven work, microbiology has returned to the stage of observation.
Like the naturalists of the past, we have been give a new lens to discover a world previously
unknown.

1.2 The Human Microbiome
The human microbiome is the collection of ecological communities of bacteria, fungi,
viruses, and other microbes that colonize our bodies. The commensal bacteria perform a variety
of beneficial roles including immune system education, vitamin production, and protection form
invading pathogens. They inhabit nearly every surface of the human body exposed to the external
environment including the skin, gut, vagina, oral cavity, and even the upper airways of the lung
(Grice & Segre 2012; Charlson et al. 2012). While some constituents are conserved, the structure,
composition, and biomass of the human microbiome vary greatly between body sites and are
exquisitely sensitive to variation in their microenvironment. As such, the microbiome often
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reflects the health of its host, and in many cases may be a driving factor in the initiation or
persistence of disease (Cho & Blaser 2012).

The complexity of human-microbe interactions is staggering in its breath and depth. Even
the bacterial component alone, by far the best studied, is unfathomable in its scale. The average
human body is composed of 30 trillion cells, but it is colonized by approximately 39 trillion
bacterial cells (Sender et al. 2016). These commensal bacteria interact with their human host via a
wealth of secreted compounds, metabolites, antigens, and occasionally toxins. They also interact
with each other by competing for nutrients, producing antibiotics and bacteriocins, facilitating
horizontal gene transfer, and myriad other antagonistic and mutualistic interactions. Nowhere is
this more apparent than in the gut, where the microbiome has been shown to contribute to disease,
modulate physiologic responses to diet, and provide protection from invading pathogens
(Shreiner et al. 2015). There is mounting evidence for the role of the gut microbiome in
inflammatory bowel diseases (Morgan et al. 2012), coronary artery disease (Koeth et al. 2013),
obesity (Turnbaugh et al. 2006), insulin resistance (Suez et al. 2014), depression (Foster &
McVey Neufeld 2013), hepatic encephalopathy (Bajaj et al. 2012), and differential drug
absorption (Clayton et al. 2009). Moreover, it is well established that antibiotic perturbations of
the gut microbiota leads to dysbiotic states (Modi et al. 2014), which increase the risk of
developing Clostridium difficile infections (Buffie et al. 2014), which can be successfully treated
with fecal microbiota transplantation (Kassam et al. 2013).

The centrality of the gut microbiome in many ailments has raised the possibility that the
microbiome of other body sites may hold similar promise as driving determinants of health and
disease. Indeed studies of the human microbiome across the body have borne out this belief.
3

Alterations in the vaginal microbiome have been linked to bacterial vaginosis (Mayer et al. 2015),
chronic yeast infections (Liu et al. 2013), and preterm delivery (DiGiulio et al. 2015). The oral
microbiome may contribute to periodontal disease and dental caries (Wade 2013). Even the lung,
which is generally thought to be a sterile site, has been shown to have a microbiome that can
reflect the immunity status of its host (Charlson et al. 2012; Wang et al. 2016; Young et al. 2014;
Quinn et al. 2014).

Seminal work put forth by Grice et al characterized the healthy skin microbiome and how
it varies spatially across the body(Grice et al. 2009). Subsequent studies have since linked
dysbiosis of the skin microbiome with psoriasis (Takemoto et al. 2014; Alekseyenko et al. 2013;
Ganju et al. 2016), chronic wounds (Grice et al. 2010; Gardner et al. 2013), acne (Fitz-Gibbon et
al. 2013), and atopic dermatitis (Kong et al. 2012); however, whether the skin microbiome plays a
causative or reactive role remains to be established. The majority of these studies implemented
cross-sectional study designs, and those with longitudinal analyses have been limited by sample
number. Consequently, the temporal dynamics of the skin microbiome in disease are poorly
understood and may yield better understanding and potential therapeutic targets for diseases of
the skin. The work presented here endeavors to advance our understanding in this regard by
characterizing the microbial dynamics of chronic wounds and psoriasis and their associations
with clinically meaningful outcomes.

1.3 Microbiome Workflow
Microbiome studies can be broadly classified into metataxonomic and metagenomic
analyses. Metataxonomic studies, the focus of this work, involve the sequencing of evolutionarily
4

conserved marker genes, which serve as a proxy for taxonomic classification. The 16S rRNA
gene has been extensively used to characterize prokaryotic communities, whereas the 18S rRNA
gene and the internal transcribed spacer (ITS) regions are used for fungal communities.
Bacteriophage and other viruses do not possess universally conserved genes, making
metataxonomic analyses impossible to perform. These marker genes contain conserved and
hypervariable regions, which allow for universal primer annealing and taxonomic classification
respectively. The 16S rRNA gene is approximately 1.5 kilobases in length and contains 9
hypervariable regions, denoted V1 through V9. Because of the current limitations in sequence
lengths generated by next-generation sequencing technologies, specific sub-regions must be
chosen for amplification and sequencing. The most commonly used sub-regions are V1-V3 and
V4, however, resident evidence suggests that the V1-V3 region introduces less bias for skin
communities (Meisel et al. 2016). In contrast, metagenomic studies involve shotgun sequencing
the combined genomic content of the entire community. Metagenomic studies provide both a
taxonomic and functional perspective of the community, but require much greater sequencing
depth, computational resources, and controlling for human contamination.

Metaxonomic studies begin with the aggregation of similar sequences into clusters,
termed operational taxonomic units (OTU), which serve as proxies for species (Kopylova et al.
2016). OTUs are taxonomically identified and are then used to estimate alpha and beta diversity
by a variety of metrics. Alpha metrics measure the diversity intrinsic to a sample by quantifying
the richness (number of observed OTUs) and evenness of the community. Beta metrics measure
the amount of shared diversity between samples. Diversity metrics differ in how abundance or
phylogenetic relationships are weighted, which reveal different components of the community
structure. While there is considerable diversity in specific algorithms or metrics applied, the
5

popular adoption of software packages such as QIIME and MOTHUR has partially standardized
these analyses (Caporaso et al. 2010; Schloss et al. 2009).

1.4 The Structure and Function of Human Skin
The skin is one of the most exposed organs of the body and serves a critical role as the
primary interface between the external environment and the underlying tissues. The skin provides
a barrier against constant physical, chemical, and immunological insults. It also performs key
homeostatic functions in regulating body temperature, fluid balance, and production of vitamin D
(Telofski et al. 2012). The skin covers approximately 1.8 m2 with multiple microenvironments
created by variation in exposure (folds, invaginations, and clothing), sweat and sebum production,
and hair distribution. The diversity of skin microenvironments is reflected by the rich and
complex communities of microbes that colonize the skin. Thus, to fully understand the skin
microbiome and its interactions with the skin, we must be familiar with the biology and topology
of the skin.

The skin is composed of two layers, the dermis and epidermis, which rest above a layer
of subcutaneous fat (Simpson et al. 2011). The deeper of the two, the dermis is composed of
dense, irregular connective tissue and contains a variety of receptors, vessels, and glands involved
in maintenance of epidermal integrity. Superficial to the dermis is the epidermis, which itself is
composed of four layers of keratinocytes various stages of development. The stratum basale, as
the name implies, is the basal layer, which is separated from the dermis by the epidermal
basement membrane (Fuchs & Raghavan 2002). This layer contains the undifferentiated stem
cells that undergo asymmetric division to give rise to the stratum spinosum. In this layer, the
6

immature keratinocytes begin to flatten and develop lamellar bodies and keratin fibrils. As
keratinocytes continue to mature, they develop into the stratum granulosum, characterized by
abundant keratohyalin granules. The granules contain filagrin, keratin, loricin, and involucrin,
which are critical for the proper barrier function of the epidermis. To complete the differentiation
process, the keratinocytes then anucleate and fully flatten forming the stratum corneum. Cells at
this stage are termed corneocytes for their highly cornified envelope (Candi et al. 2005).

The orderly layers of the epidermis are regularly interrupted by hair follicles and glands
that extend into the dermis. Sebaceous glands specialized in the secretion of a lipid-rich substance
termed sebum, which contributes to the waterproofing of the skin (Zouboulis & Boschnakow
2001). The glands are often associated with hair follicles forming pilosebacious units, particularly
prevalent on the face and scalp. These units provide an ideal environment for anaerobic bacteria
that metabolize the secreted lipids into free fatty acids, contributing to the relatively acidic pH of
the skin (Puhvel et al. 1975). Sweat glands in contrast are distributed throughout the body,
though they are particularly concentrated in the axillae, palms, soles, and forehead (Lu & Fuchs
2014). The eccrine sweat glands produce a salty solution primarily composed of sodium-chloride
and water, which is critical to their role in thermoregulation. The apocrine sweat glands secrete a
more specialized solution including steroids, proteins, and lipids, which are thought to be
involved in pheromone production and are particularly active during puberty. The apocrine
secretions, initially odorless, are metabolized by microbes into volatile compounds associated
with body odor.

Critical to the barrier function of the skin is its role in protection again invading
pathogens. Skin immunity is mediated primarily by keratinocytes and cells of both the adaptive
7

and innate immune system (Pasparakis et al. 2014). As part of its immunological role,
keratinocytes produce a variety of antimicrobial peptides, which function as broad antibiotics.
Keratinocytes express Toll- and Nod-like receptors, which are activated by conserved molecules
produced by commensals and pathogens alike (Heath & Carbone 2013). When activated,
keratinocytes are prolific producers of proinflammatory cytokines and chemokines, which recruit
nearby cells of the immune system. Langerhans cells, a dendritic cell subset, monitor the dermis
and epidermis for microbial antigens, though they are also involved in promoting tolerance to
self-antigens. When activated by foreign antigen, Langerhans cells will migrate to the skindraining lymph nodes and present the offending antigen to naïve T-cells. Differentiated effector
and memory T-cells then migrate to the skin to address the potential pathogen.

1.5 The Healthy Skin Microbiome
The skin features rich and complex communities of microbes, which reflect the diversity
of microenvironments of the body. Body sites may be sebaceous, moist, or dry; haired or
glabrous; exposed or occluded. They vary in humidity, pH, temperature, and level of
antimicrobial peptides. These features define the microenvironments that microbes interact with
and are major determinants of the community composition and structure. In general, the skin is
dominated by four major taxa – Propionibacterium, Staphylococcus, Corynebacterium, and
Proteobacteria – though the relative abundances of each vary with body site (Grice & Segre
2011). Foundational work by Grice et al revealed the topographical diversity of the bacterial
microbiome at 20 distinct body sites, characterized as moist, sebaceous, or dry (Grice et al. 2009).
Sebaceous sites were dominated by Propionibacterium species, with some contributions of
Staphylococcus species. The moist sites were dominated by a combination of Corynebacterium,
8

β-Proteobacteria, and Staphylococcus species, though the distribution between these three varied
considerably. The dry sites in contrast are more diverse, with no taxa being particularly dominant,
however, increased prevalence of β-Proteobacteria and Flavobacteriaceae species were apparent.
Sebaceous sites exhibited low levels of community diversity, whereas the dry sites exhibited the
highest levels. This was found to be true for both the number of observed OTUs (richness) and
Shannon Diversity Index (evenness).

Body sites have been shown to be the greatest determinants of community structure in
healthy individuals. Community differences between body sites of the same individual are
significantly larger than those between individuals of the same body site (Costello et al. 2009).
Even so, differences between individuals at the same body site are greater than those between
contralateral samples of the same subject and body site. Similarly, individuals are more similar to
themselves over time (1-3 months), than between individuals at the same time point (Grice et al.
2009; Costello et al. 2009). Importantly, skin microbiome was shown to be less stable than
communities of the gut or mouth (Costello et al. 2009), however, a recent metagenomic analysis
found the skin to be more stable than previously reported (Oh et al. 2016).

Body sites also vary in the permissiveness of accepting microbiome transplants from
other body sites. Costello et al found that the microbiome of the forehead, a sebaceous site, was
significantly more resistant to microbiome transplants than the forearm, a dry site (Costello et al.
2009). The forehead also regained its original community structure faster than the forearm. This
suggests that sebaceous sites exert more selective pressures on the microbiota than dry sites.
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Fungal communities colonizing the skin have not been as extensively studied, but are
beginning to emerge (Findley et al. 2013). Malassezia species were found to dominate fungal
communities at most body sites, though species level signatures could be detected. In contrast, the
fungal communities of the foot exhibited much greater levels of diversity and had significant
contributions from Aspergillus and Epicoccum. Interestingly, community types clustered by body
site geography rather than physiologic niche (sebaceous, moist, dry). This suggests that the fungal
communities are less sensitive to these selective pressures.

The microbiota of the skin develops with age, beginning with birth and normalizing with
the completion of puberty. Neonatal skin is markedly different from that of adults – the stratum
corneum is thinner and composed of smaller corneocytes (Stamatas et al. 2010), the epidermal
barrier is more permeable as a result of lower lipid content (Nikolovski et al. 2008), and the skin
pH is more alkaline (Giusti et al. 2001). The cutaneous microbiome of neonates is marked by
high levels of Staphylococcus and Streptococcus, but body-site specific patterns begin to emerge
by six months of age (Capone et al. 2011). Using Tanner stages to distinguish between children
and adults, a study found that subjects in late puberty had developed the adult-like dominances of
Propionibacterium and Corynebacterium (Oh et al. 2012). Even whether a neonate is born
vaginally or via Caesarean section has profound differences on the composition of the skin
microbiota (Dominguez-Bello et al. 2010); however, it is unclear what impact this has on health
outcomes. In contrast to age, the effect of gender on the skin microbiome is less clear and likely
dwarfed by individual-specific forces (SanMiguel & Grice 2014).

The interactions between the immune system and the cutaneous microbiome are of
critical importance in determining the efficacy of the former and the composition of the latter
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(Belkaid & Tamoutounour 2016). There is a growing appreciation for the role of the skin
microbiota in educating the immune system. One study compared the cutaneous immunity
profiles of germ-free (GF) and specific pathogen-free (SPF) mice (Naik et al. 2012). This study
documented significant decreases in the production of IFN-γ and IL-17A and increased presence
of Foxp3+ regulatory T-cells in GF mice. When mono-colonized by the human commensal
Staphylococcus epidermids, the IL-17A deficiency was abrogated. When applied to GF mice
infected with Leishmania major, S. epidermidis mono-colonization was enough to correct the
defective immune response normally mounted by GF mice. S. epidermidis has also been shown to
increase the production of antimicrobial peptides and proinflammatory cytokines, through its
activation of TLR2, leading to improved responses to infection with the bacteria Group A
Streptococcus and human papilloma virus (HPV) (Lai et al. 2010; Wanke et al. 2011; Percoco et
al. 2013). Lipoteichoic acid, a component of gram-positive cell walls, may also modulate TLR3mediated inflammation in keratinocytes during acute injury (Lai et al. 2009). The immune system
also shapes the cutaneous microbiome as demonstrated by studies in humans with primary
immunodeficiencies (Oh et al. 2013). Immunocompromised subjects’ skin was marked by
increased permissiveness to the opportunistic pathogen, Serratia marcesens, and other atypical
bacteria. Longitudinal stability and site specificity were also noted to be less pronounced in these
subjects, suggesting that the immune system plays an active role in defining the cutaneous
microbiome.

1.6 Wound Healing and Chronic Wounds
On occasion the integrity of the skin may be compromised by traumatic injury or some
other insult to the skin resulting in a wound. The wounded skin then commences a series of
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organized and well-characterized processes collectively referred to as wound healing. Wound
healing can be divided into four phases with considerable overlap: hemostasis, inflammation,
proliferation, and remodeling; however, some include hemostasis as a part of the inflammation
phase (Velnar et al. 2009). The process begins with coagulation and the formation of a fibrin-rich
clot, ensuring hemostasis and additionally providing a matrix for tissue regeneration. Platelets,
embedded in the clot, degranulate, releasing chemokines and growth factors critical for
facilitating keratinocyte and leukocyte migration to the wound and cellular proliferation (Gurtner
et al. 2008).

Soon after, the early inflammation phase commences with the infiltration of neutrophils
into the wounded tissue (Hart 2002). Their primary purpose is to prevent infection by
phagocytosing bacteria and cellular debris. Neutrophils also produce elastases and collagenases
that assist in degrading the extracellular matrix, facilitating migration of other cells. The late
inflammatory phase begins 48-72 hours after injury and is characterized by the migration of
macrophages to the wound, which continue the process of phagocytosis and crucially, produce
copious amounts of additional growth factors promoting wound healing.

The proliferative phase begins at approximately the third day following injury and may
persist for two weeks or more depending on the extent of injury (Velnar et al. 2009). Fibroblasts
migrate into the wound and produce hyaluronan, proteoglycans, fibronectin, and pro-collagen,
which replace the makeshift fibrin-matrix created during the coagulation phase. After the first
week, fibroblasts mature into myofibroblasts, adhere to the extracellular matrix and contract,
pulling the edges of the wound closer together. During this phase, new blood vessels develop to
perfuse the regenerating tissue with a process termed angiogenesis. Endothelial cells proliferate
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and migrate into the wound following chemotactic and proliferative signals. Together these
processes lead to the creation of vasculature, connective tissue, and extracellular matrix that
collective is termed granulation tissue. Re-epithelialization, the migration and proliferation of the
epithelial keratinocytes, begins as early as the first day of wounding but is most pronounced
during the proliferative phase.

Finally, the wound undergoes the remodeling phase, during which the healing tissue is
remodeled into mature, healthy skin. This includes thickening, organizing, and cross-linking of
collagen bundles and degradation of hyaluronic acid and fibronectin fibers. This process develops
the tensile strength of the wound and may take weeks to years to finish, depending on the size and
location of the injury.

In chronic wounds, this process is delayed or halted in the inflammatory phase. In the
case of diabetic foot ulcers, a common and costly complication of diabetes, these wounds may
persist for months to years before healing or in many cases terminating in amputation (Wolcott
2015). Chronic diabetes results in significant impairments of upwards of 100 physiologic factors,
dramatically increasing the risk of foot ulceration and impeding nearly all aspects of wound
healing (Brem & Tomic-Canic 2007). The hyperglycemic state of subjects with diabetes results in
the development of distal neuropathies and peripheral vascular disease. The severity of these
defects is a function of distance, which is why the distal extremity of the foot is the first and most
affected.

Diabetic distal neuropathy is manifested in autonomic, motor, and sensory deficits
(Falanga 2005). Autonomic dysfunction leads to decreased sweat and sebum production resulting
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in dry skin prone cracking, injury, and infection. Foot deformities may develop as a consequence
of motor defects, creating bony protuberances and other sites vulnerable to mechanical stress.
Sensory deficits exacerbate the situation, by increasing the risk of injury due to repetitive or acute
trauma. More importantly, diabetics with distal neuropathy are often unaware their injury, thus
foot ulcers continue to be exposed to trauma and infection before receiving any medical
intervention. All of this is compounded by deficiencies in phagocytic activity, growth factor
production, cellular migration, angiogenesis, and extracellular matrix accumulation, which
impede effective wound healing (Brem & Tomic-Canic 2007).

1.7 A Note on Terminology
The study of the human microbiome is relatively new and its vocabulary is rapidly
evolving and often ambiguous. The word microbiome is used generally to describe all microbes
and their genomes inhabiting a niche, however, it is can also be used to describe the bacterial
component specifically, with mycome and virome referring to the fungal and viral components
respectively. For the remainder of the text, I will use distinguish between the bacterial, fungal,
and viral components using these terms and adopt the convention of distinguishing between the
actual cells, microbiota/mycobiota, and the collective genetic content, microbiome/mycome.
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CHAPTER 2 – Temporal Stability In Chronic Wound Microbiota Is Associated
With Poor Healing
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2.1 Abstract
Microbial burden of chronic wounds is believed to play an important role in impaired
healing and development of infection-related complications. However, clinical cultures have little
predictive value of wound outcomes, and culture-independent studies have been limited by crosssectional design and small cohort size. We systematically evaluated the temporal dynamics of the
microbiota colonizing diabetic foot ulcers, a common and costly complication of diabetes, and its
association with healing and clinical complications. Dirichlet multinomial mixture modeling,
Markov chain analysis, and mixed-effect models were used to investigate shifts in the microbiota
over time and its associations with healing. Here we show for the first time the temporal
dynamics of the chronic wound microbiome. Microbiota community instability was associated
with faster healing and improved outcomes. DFU microbiota were found to exist in one of four
community types that experienced frequent and non-random transitions, which corresponded to
the healing time. Exposure to systemic antibiotics destabilized the wound microbiota, rather than
altering overall diversity or relative abundance of specific taxa. This study provides the first
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evidence that the dynamic wound microbiome is indicative of clinical outcomes and may be a
valuable guide for personalized management and treatment of chronic wounds.

2.2 Introduction
Chronic, non-healing wounds affect 6.5 million patients annually in the US and are an
increasing public health and economic threat, exceeding estimated annual treatment costs of $9.7
billion (Bickers et al. 2006). Chronic wounds almost always affect individuals with an underlying
predisposition (e.g. obesity, advanced age, diabetes) and are often disguised as a comorbid
condition. A major type of chronic wound is the diabetic foot ulcer (DFU), a common
complication of diabetes that results from neuropathy coupled with mechanical stress and tissue
breakdown. Those with diabetes have a 15-25% lifetime incidence of DFU (Valensi et al. 2005)
and result in amputation in 15.6% of cases (Ramsey et al. 1999). Projections estimate that
diabetes will continue to increase in prevalence (Guariguata et al. 2014); thus addressing
management and treatment strategies for this complication is critical.

Microbial bioburden is believed to contribute to impaired healing of chronic wounds and
it is estimated that over 50% of DFUs are infected upon presentation (Prompers et al. 2007);
however, infections are difficult to diagnose due to the diminished or absent clinical signs in
DFUs (Glaudemans et al. 2015). Without clinical suspicion, wound cultures provide little
diagnostic value, as bacteria colonize all open wounds. Our previous work demonstrated that
clinical cultures underestimate bacterial diversity and load when compared to culture-independent
techniques, based on the prokaryote-specific 16S ribosomal RNA (rRNA) gene. Multiple
dimensions of the microbiota may be important, including microbial diversity, microbial load,
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and abundance of potential pathogens (Gardner and Frantz 2008). Although other studies have
used culture-independent methods to examine DFUs and other chronic wound microbiomes, these
studies employed cross-sectional designs (Dowd et al. 2008; Price et al. 2009; Gontcharova 2010;
Gardner et al. 2013; Wittebole et al. 2014; Wolcott et al. 2015) and the relationship between the
wound microbiome and outcomes has not been rigorously examined.

Microbial communities exhibit a wide range of stabilities across the human body (Ding
and Schloss 2014; Flores et al. 2014); however, what these differing stabilities mean for the
health of the community or the host remain poorly understood. Very little is known about the
dynamics of the wound microbiota during healing, deterioration, or exposure to antibiotics. To
date, no study has investigated the microbial dynamics of chronic wounds. These dynamics may
contain information about the vulnerability of the wound to opportunistic infections or provide
insight as to the origin of stalled wound healing. It is critical to study these dynamics to enhance
our understanding of chronic wounds and improve our ability to effectively treat them.

We address several important limitations of previous studies by performing a study
designed to capture the longitudinal dynamics of microbiota colonizing DFUs and examining the
association between the DFU microbiome and clinical outcomes. Microbiota were sampled from
DFUs every two weeks for 26 weeks or until healed. We employed high throughput sequencing
of the 16S rRNA gene to define multiple metrics of the microbiome, including diversity, stability,
and relative abundance of potential pathogens and identified microbiomic features associated
with DFU clinical outcomes. Though our study was focused on the microbiota in DFU, many of
these findings may be true of other chronic wounds and should be considered in future studies
and treatments of chronic wounds.
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2.3 Results
We enrolled 100 subjects into a prospective, longitudinal cohort study to analyze
temporal dynamics of DFU microbiota and association with outcomes using culture-independent
approaches. DFU microbiota was collected at initial presentation (baseline) and resampled every
two weeks until: 1) DFU healed; 2) lower extremity amputation; or 3) the conclusion of 26 weeks
of follow up. All subject received standardized treatment of surgical debridement and offloading.
Of the 100 enrolled subjects, 31 experienced an infection-related complication, defined as: 1)
amputation; 2) wound deterioration, or 3) development of osteomyelitis. Table S1 summarizes
clinical factors by complication status.

2.3.1 Characterization of the DFU microbiota at baseline
DFU microbiomes were determined by sequencing of hypervariable regions V1 through
V3 of the 16S ribosomal RNA (rRNA) gene. The most abundant genus identified was
Staphylococcus, present in 345 of the 349 samples, with an average relative abundance of
22.77%. The second, third, and fourth most abundant genera were Streptococcus (11.98%; 318 of
349 samples), Corynebacterium (11.46%; 346 of 349 samples), and Anaerococcus (7%; 300 of
349 samples), respectively. All other genera represented <5% of bacterial relative abundance in
this dataset. A more detailed characterization can be found in Table S2. We further classified
Staphylococcus operational taxonomic units (OTUs) to species level for 79.5% of the OTUs. Of
the 22.77% attributed to Staphylococcus, 13.3% was classified as S. aureus, 5.3% was S.
pettenkoferi, and 4% was not further classified. While S. aureus is a common DFU isolate, the
high abundance of S. pettenkoferi was surprising as this species was only recently characterized
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in 2007 (Trülzsch et al. 2007), though it was identified as the cause of osteomyelitis in patient
with a chronic DFU in France (Loïez et al. 2007).

2.3.2 DFU microbiota can be partitioned into four community types
We assigned DFUs to community types with the Dirichlet multinomial mixture (DMM)
model-based approach (Holmes et al. 2012). The DMM model supposes a more biologically
relevant distribution of data, which overcomes limitations of alternative methods such as k-means
(Holmes et al. 2012) and PAM clustering (Ding and Schloss 2014). The DFU microbiomes were
clustered into 4 groups, or Community Types (CT), by minimizing the Laplace approximation
(Fig. S1). The top five differentiating taxa contributed 48.9% of the total difference between a
one and four component model, though the major distinguishing taxa were Streptococcus (25.6%)
and S. aureus (11.8%) (Fig. 1A). CT3 DFUs were characterized by high relative abundances of
Streptococcus (median = 64.0%). CT4 DFUs were comprised of relatively high levels of S.
aureus (median=23.8%). CT1 and CT2 were highly heterogeneous with no dominant taxa
contributing more than a median of 5% of total relative abundance. This was also reflected by
Theta values, a measure of cluster variability with smaller values corresponding to highly variable
communities, which were 3.7 and 6.9, for the CT1 and CT2 compared to 16.4 and 10.5 for CT3
and CT4, respectively. Community type summaries are described in greater detail in
Supplemental Table 3.

To better visualize how CTs were associated with microbiota composition and clinical
features, we generated a biplot depicting these relationships (Fig. 1B). As would be expected, the
taxa vectors for Streptococcus and S. aureus are closely associated with the CT3 and CT4,
respectively. Interestingly, the samples with the highest proportion of S. aureus are not included
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in CT4, demonstrating the importance of the whole community in distinguishing clusters.
Streptococcus was closely associated with HbA1C levels and anaerobe levels with ulcer depth.
Serum C-reactive protein levels (CRP) and white blood cell counts (WBC), both measures of
inflammation used to inform the diagnosis of infections, localized separately with CT4 and CT3,
respectively. Subject outcomes also contributed to data separation, with amputation localizing
with CT1 and CT2, and unhealed subjects localizing with CT4.

2.3.3 The frequency of Community Type transitions in DFU are associated with
clinical outcomes
We next investigated the stability of the CTs by exploring the frequency and type of CT
transitions. The DFU microbiota was highly dynamic with CT transitions occurring every 1.76
study visits (approximately 3.52 weeks) on average (Fig. 2A). Transition frequencies were
significantly associated with subject outcomes (healed = 1.60, unhealed = 2.04, amputation =
3.08 study visits/CT-transition). We further subdivided healed subjects into those whose ulcers
closed in <12 weeks and those closed in >12 weeks. Consistent with our analysis, the faster
healing subjects experienced greater transition frequencies (<12 weeks = 1.45, >12 weeks 2.11
study visits/CT-transition, Wilcoxon p-value = 0.011).

We then questioned whether transition patterns between CTs were related to ulcer
outcomes. By quantifying transitions between CTs we could represent the data as a Markov
chain, with nodes representing CTs and edges representing transition frequencies by their weight
(Fig. 2B). The transition patterns between those that healed in <12 weeks and those that healed in
>12 weeks were significantly different (p-value < 0.0001). In those who healed in <12 weeks,
CT1 and CT2 dominated the transitions and were noted to have high self-transition rates of 0.74
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and 0.53, respectively. In contrast CT3 and CT4 experienced lower self-transition rates of 0.23
and 0.29, and had a predilection for transitioning to CT2. For subjects that took >12 weeks to
heal, there is a marked increase in self-transitions, with ulcers stalling in CT3 and CT4 at rates of
0.45 and 0.84, respectively, indicating that the stability of these CTs may be detrimental to wound
healing. Analysis of the stationary distribution and expected recurrence time revealed similar
trends (Table S4). The presence or absence of transitions between CT3 and CT4 also
differentiated the two groups, with no recorded instances in wounds healing in <12 weeks.
Together these findings suggest that community stability reflects a delayed healing phenotype.

2.3.4 DFU with more dynamic microbiota heal faster than those with less
dynamic microbiota
To address more subtle patterns of variation, which may not be apparent when examining
broad community types, we used the inter-visit weighted UniFrac (WUF) distance as a proxy of
stability. The weighted UniFrac metric measures the proportion of shared OTUs, their
phylogenetic relationships, and their relative distributions on a scale of 0 to 1, with higher values
indicating greater instability. We generated mixed-effect linear regressions to model the
relationship between microbiota instability and time required to heal in those that healed within
24 weeks. This model suggests that all ulcers are slowly stabilizing at a rate of -0.024/visit;
however, slow healing ulcers begin in a more stable state (-0.036 per visit required to heal) (Fig.
3A). Because mixed-effect models do not allow generation of a traditional R2 value, we
calculated marginal and conditional pseudo-R2 values, which reveals an estimate of the variance
due to the fixed effects alone and the combined model of fixed and random effects respectively.
The marginal R2 was estimated to be 0.201 and the conditional to be 0.280, indicating that our
model explains a moderate amount of the variation.
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The first inter-visit distance, between the baseline study visit and following visit, includes
the effect of the initial surgical debridement. Thus it was possible that the high instability in faster
healing wounds was an artifact of the first study visit being weighted more. To address this
concern, we investigated the relationship between healing time and the amount of change
between baseline and the following visit (2 weeks’ time) using a traditional linear model. We
found the same negative association between healing time and the inter-visit distance (R2 = 0.16,
p<0.0001) (Fig. 3B), suggesting the effect is independent of debridement.

2.3.5 Effect of antibiotics on temporal stability in DFU microbiota
During the course of the study, 32 subjects required the administration of antibiotics,
which afforded us the opportunity to glean the effects of antibiotics on ulcer microbiomes.
Antibiotic exposure did not drive microbiota variation in our samples (Fig 1B). Furthermore, we
did not detect any significant changes in community diversity as measured by the Shannon index
or OTU richness, perhaps due to unique interactions between specific antibiotic classes and
personal microbial communities. We assessed the potential for antibiotics to disrupt microbial
communities using the inter-visit WUF distances as before and by binning antibiotics into distinct
categories based on their class and mechanism of action. We did not detect significant differences
in microbial stability due to antibiotic class. However, in half of the cases, the antibiotics were
prescribed to treat infections not involving the studied ulcer (e.g. other ulcers, urinary tract
infection, upper respiratory infection, sinus infection). When we examined the subjects treated
specifically for the study ulcer, we found that antibiotics administered produced significantly
higher community disruption than if the antibiotic was given for a different indication (Fig. 4A).
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In some cases, during the same time period that antibiotics were administered, the ulcer
was designated as having a complication (wound deterioration or osteomyelitis). We modeled
how these complications interacted with the antibiotics using mixed-effect linear regressions as
before (Fig. 4B). We found that both complications and antibiotics contributed to community
disruption, though the larger effect was noted for antibiotics (WUF = 0.084 and 0.140
respectively). Furthermore, targeted antibiotics and complications had an additive effect on the
amount of community disruption (WUF = 0.201).

2.4 Discussion
Ours is the first study to explore the temporal dynamics of the human chronic wound
microbiota. Microbiome studies in other body sites have shown that disease states are associated
with less stability (Martinez et al. 2008; Jenq et al. 2012; DiGiulio et al. 2015). Surprisingly,
DFUs that experienced delayed healing or resulted in amputation were associated with increased
stability, while the inverse was true for faster healing wounds. One way of interpreting these
findings is to conclude that there is no “normal” DFU community. A wound is by definition an
abnormal and transient state in physiology. As such, colonizing bacteria should be considered
opportunistic and unlikely to have evolved harmonious methods of existing with the host. From
this perspective, instability in the microbiome is a reflection of effective control of wound
bacteria, which prevents any community structure from stabilizing. In contrast, a DFU with a
stable outgrowth of certain bacteria reflects a stalled healing state where the colonizing bacteria
have overridden the host’s defenses.

We found that the DFU microbiome can be partitioned into 4 community types. Increased
community type transitions were associated with improved healing rates; however, these
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community type transitions were not random. In quickly healing ulcers, CT1 and CT2 were
substantially more likely to remain unchanged, whereas CT3 and CT4 were more likely to
transition to CT2. In slow or unhealing wounds, we found that CT3 and CT4 became much more
resilient. These findings suggest that the prognostic capacity of transition frequencies would be
augmented by information of community structure. Further studies are needed to delineate cause
and effect relationships of the microbiota with the wound environment.

Despite the regular use of antibiotics to treat infections, little is known about their impact
on microbial communities in chronic wounds. We did not detect any differences in community
diversity or composition due to antibiotic exposure, unlike the gut where exposure to certain
antibiotics is known to decrease diversity levels, predisposing to infection by Clostridium difficile
(Dethlefsen and Relman 2011; Stein et al. 2013). Instead, as in other body sites (Keeney et al.
2014; Modi et al. 2014; Zhang et al. 2014; Mayer et al. 2015), antibiotics disrupted the
microbiota. The extent of community disruption was not dependent on the class of antibiotic;
rather it was whether the antibiotic was targeted towards the ulcer being studied. However, our
analysis is limited by the biweekly sampling frequency, limiting the detection of short-lived
changes.

In some reports, over half of DFUs are infected at the time of presentation (Prompers et
al. 2007); however, identifying reliable criteria to diagnose an infection is complicated by the
attenuated response to infections in diabetic persons (Brem and Tomic-Canic 2007). While our
results would benefit from validation in larger cohorts, and their applicability to other types of
chronic wounds needs to be tested, we provide evidence that the temporal dynamics of the wound
microbiome may be useful for identifying stalled wounds requiring antibiotic treatment. We
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envision that these findings will ultimately guide clinicians in the management of chronic wounds
in a personalized manner.

2.5 Materials and Methods
2.5.1 Study Design
A prospective, longitudinal cohort design was used to examine DFU microbiota
and outcomes in 100 subjects. DFU microbiota was collected at initial presentation
(baseline) and resampled every two weeks until: 1) DFU healed; 2) lower extremity
amputation; or 3) the conclusion of 26 weeks of follow up. The Institutional Review
Boards at the University of Iowa and the University of Pennsylvania approved all study
procedures.

2.5.2 Setting and Sample
Subjects were enrolled from September 2008 through October 2012 at the University of
Iowa Hospitals and Clinics (UIHC) and the Iowa City Veteran’s Affairs Medical Center (VA).
Subjects were recruited through local media advertisements and from outpatient clinics at UIHC
and the VA. The target population was diabetic adults (i.e., 18 years of age or older) with a DFU
on the plantar surface of the foot. Individuals meeting these criteria were enrolled after providing
informed written consent.

We standardized the management of the study DFUs after enrollment, including ulcer
dressings (i.e., Lyofoam®, Molnlycke Health Care), devices used for offloading (i.e., total
contact casts were used for 87 subjects; DH boots for 13 subjects), and ulcer debridement (i.e.,
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aggressive sharp debridement of necrotic tissue in the wound bed was completed at baseline and
callus on the wound edge was removed every two weeks), in order to minimize the number of
factors unrelated to ulcer bioburden that could impact DFU outcomes. DFU management did not
include antimicrobial dressings, topical antimicrobials, and/or systemic antibiotics, unless an
infection-related complication was present at enrollment or occurred during follow-up. Baseline
data were collected immediately after enrollment. Study data were collected every two weeks
until one of the study endpoints was reached.

2.5.3 Study Variables
Clinical factors: The research team measured a set of clinical factors in order to identify
pertinent co-variates for the analyses and to comprehensively describe the study sample. At
baseline, demographic data, diabetes type and duration, and duration of study ulcer were collected
using subject self-report and medical records. Standard laboratory tests were used to measure
baseline glycemic control (haemoglobin A1c levels), as well as immune (White blood cell count)
and inflammatory markers (C reactive protein). The research team assessed each subject for
ischemia using toe-brachial index and for neuropathy using 5.07 Semmes-Weinstein
monofilament. Transcutaneous oxygen pressure was measured at baseline and at each follow-up
visit, using a transcutaneous oxygen monitor (Novametrix 840®, Novametrix Medical Systems
Inc.). Ulcer location was categorized as forefoot, midfoot, or heel.

Microbiome: Ulcer specimens were collected using the Levine technique. After cleansing
with non-bacteriostatic saline, an Amies swab (Copan, Italy) was rotated over a 1-cm2 area of
viable wound tissue in the center of the wound bed for five seconds, using sufficient pressure to
extract wound-tissue fluid, DNA was isolated from swab specimens as previously described
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(Gardner et al. 2013). Amplification of the 16S V1-V3 region was performed as described
previously (Meisel et al. 2016), using the Illumina MiSeq platform with 300 bp paired-end ‘V3’
chemistry. This resulted in a dataset of 7,702,607 high quality, classifiable sequences used in the
final analysis, with a mean of 22,070 (range 1,206-69,167) sequences per sample.16S rRNA
sequence pre-processing followed methods described previously (Meisel et al. 2016), modified by
performing denovo OTU clustering via UCLUST, assigning taxonomy with BLAST, and
subsampling at 1200 sequences per sample. Sequences corresponding to the taxa “Geobacillus”,
“Bacillus”, and “Lactococcus” were removed as these were identified as contaminants in the
negative controls. QIIME 1.9.0 (Caporaso et al. 2010) was used for initial stages of sequence
analysis. Sequences were clustered into OTUs (operational taxonomic units, a proxy for
‘species’) using UCLUST(Edgar 2010) at 97% sequence similarity. Microbial diversity was
calculated using the following alpha diversity indices: 1) Shannon diversity index; 2) Faith’s
phylogenetic distance (PD); and 3) number of observed OTUs. Taxonomic classification of
sequences were made using BLAST, as implemented in QIIME.

Outcomes: Members of the research team, who were blinded to the microbiota status,
assessed healing and infection-related complications every two weeks. Ulcer closure was assessed
using the Wound Healing Society’s definition of “an acceptably healed wound,” a valid and
reliable definition (Margolis et al. 1996). The outcome “healed by 12 weeks” was defined as
wound closure before or at 12 weeks of follow-up. “Development of infection-related
complications” was defined as wound deterioration, new osteomyelitis, and/or amputations due to
DFU infections.
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Wound deterioration was defined as the new development of frank erythema and heat, and an
increase in size > 50% over baseline. Two members of the research team independently assessed
each DFU for erythema and heat. Two members of the research team independently assessed size
using the VeVMD® digital software system (Vista Medical, Winnipeg, Manitoba, Canada), which
was loaded on a Dell Latitude D630 laptop computer (Dell, Round Rock, Texas). Digital images
were taken that contained the ulcer, a 3x3 square-centimeter image orientation card, and a singlepoint wound-depth indicator (i.e. A cotton-tipped swab that had been placed in the deepest aspect
of the DFU and marked where the swab intersected with the plane of the peri-wound skin) and
uploaded into the VeVMD program. VevMD tools were used to trace the ulcer outline and a line
along the wound depth indicator to generate measures of depth and surface area.

Osteomyelitis was assessed using radiographs and MRI at baseline and during follow-up
visits when subjects presented with new tracts to bone, wound deterioration, elevated
temperature, elevated white count, elevated erythrocyte sedimentation rate, or elevated C-reactive
protein. If these indicators were absent at follow-up, radiographs were not retaken. Subjects
experiencing lower limb amputations had their medical records reviewed by the research team to
ensure amputations were due to DFU infection, and not some other reason.

2.5.4 Data Analyses
The R Statistical Package ({R Core Team} 2016) was used for all computations. Nonparametric Wilcoxon rank-sum tests were used to compare differences between groups. Spearman
correlations were used to correlate continuous variables. Kruskal-Wallis tests, followed by
Wilcoxon rank sum post-hoc tests, were used for categorical variables. Linear models were
calculated in base R; mixed-effect regressions were generated using the NLME package(Pinheiro
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et al. 2007). Partial and conditional pseudo-R2 values were calculated using the piecewiseSEM
package (Lefcheck 2015). Sample biplot was generated using the Breadcrumbs package as done
in (Morgan et al. 2015). Differences in Markov chain transition frequencies were tested with a
Fisher’s test and simulated p-value. Dirichlet multinomial mixture modeling was performed using
the R package Dirichlet Multinomial (v1.10.0). Counts were calculated at the highest level of
taxonomic classification. The number of community types was determined by selecting the
number of Dirichlet components that minimized the Laplace approximation of the model
evidence (Holmes et al. 2012). Each sample was assigned to the community type that had the
largest posterior probability. Inter-visit distances were calculated using the weighted UniFrac
distance between consecutive visits. If visits were discontinuous (i.e. missing sample) no
distances were reported.
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Figure 1
The DFU microbiome clusters into four Community Types. (A) DFU samples partitioned into
four clusters by Dirichlet multinomial mixture model. Mean relative abundances of bacterial taxa
in DFU samples assigned to each Community Type. Relative abundance is shown on the Y-axis.
Taxa are filtered to those with a mean abundance greater than 1%. (B) Sample similarity between
DFU microbial communities were calculated using the Bray-Curtis distance and these distances
were ordinated via non-metric multidimensional scaling. Each taxonomic contribution to
community differentiation is overlaid with black text and “x” indicating the exact location. The
impacts of various metadata are depicted as vectors labeled with gray text. Samples, taxa, and
metadata that are closer together are more related. Samples are color-coded based on community
type.
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Figure 2.
DFU Community Types are dynamic. (A) Per patient illustration of Community Type switching
grouped by outcome. Depicted on the X-axis is visit number. Each row on the Y-axis represents a
subject with a DFU. Colored boxes illustrate which Community Type was colonizing the DFU at
the indicated visit number. Empty tiles represent a missed visit, whereas gray tiles indicate that a
sample was not collected or available for analysis at that time point. The black diamonds indicate
that the patient received antibiotics since the last visit. Only subjects that participated in >1 study
visit are shown. (B) Markov chain visualization depicting the differential transition probabilities
between community types of DFUs that healed in 12 weeks or did not. Each node represents a
Community Type, arrows indicate the transition direction and probability (thickness), node-size
represents number of samples. Annotated are the self-transition probabilities.
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Figure 3
Inter-visit Weighted UniFrac distances associations with healing time for subjects that healed
within 24 weeks. (A) Inter-visit distances are shown for each subject and depict a negative trend
over time. Line and point colors represent the number of study visits that the ulcer persisted (red
= 1, green = 8). Ulcers stabilize at a rate of -0.024/visit, but start at a lower rate in those ulcers
that require more time to heal (-0.036 per visit required to heal). (B) Inter-visit distances between
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baseline and first study visit as a function of number of visits until healing. A negative correlation
is found even within this initial comparison (R2 = 0.1601, p<0.0001).
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Figure 4
Effects of antibiotics on microbial communities in DFUs. (A) Boxplot showing the inter-visit
Weighted UniFrac distances of subjects during exposure to antibiotics split by indication.
Antibiotics given for the ulcer being studied produces greater community disruption than
antibiotics given for other ulcers or other infections. Antibiotic class did not yield more
information. (B) Boxplot showing the inter-visit distances of all samples binned by event type
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(complication, antibiotics, both, or none). Antibiotics and ulcer complications both disrupt the
microbiota, and their combined effect is additive.
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3.9 Tables
Characteristic
Age (years), mean (SD)
Male sex, n (%)
White race, n (%)
Type 2 diabetes, n (%)
Duration of diabetes (years), mean (SD)
Baseline HbA1C (%), mean (SD)
Baseline WBC (mm3), mean (SD)
C Reactive Protein (mg/L), mean (SD)
Ulcer duration (weeks), mean (SD)
Toe/brachial pressure index, mean (SD)
Ulcer surface area (cm2), mean (SD)
Ulcer depth (cm), mean (SD)
Ulcer location, n (%)
Forefoot
Midfoot
Heel
Transcutaneous oxygen level (mmHg), mean (SD)

(N=100)
54.1 (11.29)
78 (78.0)
91 (91.0)
87 (87.0)
15.2 (11.31)
8.2 (1.87)
7950.5 (1905.97)
2.2 (4.78)
31.1 (40.22)
0.9 (0.25)
2.4 (3.32)
0.3 (0.33)

Did not develop infectionrelated complication
(n=69)
55.4 (12.53)
56 (81.2)
62 (89.9)
60 (87.0)
16.2 (11.55)
8.32 (1.96)
7751.5 (1916.58)
1.7 (3.04)
33.5 (42.46)
0.9 (0.27)
2.0 (3.01)
0.2 (0.27)

Developed infectionrelated complication
(n=31)
52.3 (7.65)
22 (71.0)
20 (93.5)
27 (87.1)
12.7 (10.55)
8.0 (1.67)
8387.1 (1837.52)
3.2 (7.25)
25.90 (34.81)
0.9 (0.22)
3.3 (3.84)
0.4 (0.39)

73 (73.0)
20 (20.0)
7 (7.0)
46.9 (15.11)

50 (72.5)
13 (18.8)
6 (8.7)
49.1 (13.80)

23 (74.2)
7 (22.6)
1 (3.2)
42.2 (17.00)

Total Sample

‡p-value
0.136
0.3
0.498
1
0.147
0.461
0.121
0.284
0.352
0.803
0.101
0.002*

0.585

0.057

Table S1
Patient and ulcer characteristics for the total sample and by complication status.
‡ continuous level characteristics were analyzed with an independent samples t-test;
Dichotomous characteristics were analyzed with Fisher’s Exact Test; Other categorical
characteristics were analyzed with Pearson’s Chi-Square. An asterisk (*) indicates p<0.05.

45

Combined (n = 348)

Baseline (n = 89)

Rest (n = 259)

Samples

Proportion

Samples

Proportion

Samples

Proportion

345

0.2277

86

0.2188049

259

0.2317

aureus

308

0.1331

79

0.1559

229

0.1257

pettenkoferi

287

0.0532

60

0.0290

227

0.0617

unclassified

301

0.0402

69

0.0308

232

0.0435

Streptococcus

318

0.1250

81

0.1918

236

0.1025

anginosus

51

0.0052

9

0.0008

42

0.0067

unclassified

317

0.1198

81

0.1910

235

0.0958

Corynebacterium

345

0.1121

86

0.0761

258

0.1249

Anaerococcus

300

0.0700

78

0.0745

222

0.0688

Planococcaceae

221

0.0401

58

0.0457

162

0.0383

Alcaligenaceae

194

0.0379

40

0.0020

153

0.0502

Paenibacillus

293

0.0364

79

0.0429

214

0.0342

Brevibacterium

222

0.0325

44

0.0070

177

0.0414

Comamonadaceae

321

0.0193

84

0.0227

236

0.0178

Finegoldia

245

0.0151

64

0.0111

181

0.0165

Helcococcus

207

0.0125

46

0.0144

160

0.0119

Pseudomonas

110

0.0109

20

0.0014

90

0.0142

Actinomycetales

151

0.0103

33

0.0048

118

0.0123

Bacterial Taxon
Staphylococcus

Table S2
Summary of microbial communities in DFU samples. For each bacterial taxon, the number of
samples in which it was present was tabulated, and the mean relative abundance was calculated.
These values were calculated for all samples, baseline only, and non-baseline samples. Taxa were
filtered to those whose mean abundance was greater than 0.01.
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CT 1

CT 2

CT 3

CT 4

0.0466

0.0528

0.6175

0.0275

anginosus

0.0048

0.0083

0.0032

0.0000

unclassified

0.0418

0.0445

0.6143

0.0275

0.2759

0.1710

0.0975

0.3688

aureus

0.1205

0.1012

0.0918

0.3479

pettenkoferi

0.0880

0.0374

0.0026

0.0152

sciuri

0.0025

0.0001

0.0000

0.0000

haemolyticus

0.0001

0.0004

0.0001

0.0000

unclassified

0.0649

0.0320

0.0030

0.0057

0.1586

0.0885

0.0269

0.1191

simulans

0.0024

0.0042

0.0010

0.0001

stationis

0.0000

0.0000

0.0000

0.0000

unclassified

0.1563

0.0843

0.0259

0.1190

Anaerococcus

0.0370

0.0884

0.0623

0.1759

Planococcaceae

0.0539

0.0345

0.0050

0.0442

Brevibacterium

0.0385

0.0346

0.0016

0.0419

Paenibacillus

0.0582

0.0233

0.0058

0.0206

Alcaligenaceae

0.0479

0.0495

0.0061

0.0008

Helcococcus

0.0079

0.0114

0.0079

0.0440

Finegoldia

0.0114

0.0197

0.0095

0.0254

Comamonadaceae

0.0245

0.0246

0.0020

0.0009

Peptoniphilus

0.0054

0.0134

0.0095

0.0204

Actinomycetales

0.0056

0.0185

0.0076

0.0106

Porphyromonas

0.0023

0.0141

0.0123

0.0107

Prevotella

0.0101

0.0032

0.0135

0.0026

Streptococcus

Staphylococcus

Corynebacterium

Table S3
Summaries of taxonomic composition by community type. The values shown are the mean
relative abundance for each community type. Only the top 25 taxa are shown. Species belonging
to the same genera are combined for convenience.
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Stationary Distribution Expected Recurrence Time (weeks)
<12 weeks

>12 weeks

<12 weeks

>12 weeks

CT1

0.546

0.433

3.66

4.62

CT2

0.324

0.2012

6.17

9.94

CT3

0.0343

0.1341

58.28

14.91

CT4

0.0958

0.2317

20.89

8.63

Table S4
Estimated Markov chain parameters of DFU CT transitions. The values shown are 1) the
stationary distribution, which describes the expected frequencies of CTs to be for a Markov chain,
and 2) the expected recurrence time, which estimates the average time it would take to encounter
the same CT again. Both show marked changes in the stability and frequency of CT3 and CT4
between DFUs that heal within 12 weeks and those that do not.
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CHAPTER 3 – Redefining the Chronic Wound Microbiome: Fungal Communities
Are Prevalent, Dynamic, and Associated with Delayed Healing

3.1 Contributions
The following chapter focuses on a project related to Chapter 2 that I contributed to intellectually
and analytically. Specifically, I assisted in the statistical analyses and generation of figures 1, 4,
S5, and S6.

The contents of this chapter have been accepted for publication as:
Lindsay Kalan, Michael Loesche, Brendan P. Hodkinson, Kristopher Heilmann, Gordon
Ruthel, Sue E. Gardner and Elizabeth A. Grice. 2016. Redefining the Chronic-Wound
Microbiome: Fungal Communities Are Prevalent, Dynamic, and Associated with
Delayed Healing. mBio. [In Press]

3.2 Abstract
Chronic non-healing wounds have been heralded as a silent epidemic, causing significant
morbidity and mortality especially in elderly, diabetic, and obese populations. Polymicrobial
biofilms in the wound bed, are hypothesized to disrupt the highly coordinated and sequential
events of cutaneous healing. Both culture-dependent and -independent studies of the chronic
wound microbiome have almost exclusively focused on bacteria, omitting what we hypothesize
are important fungal contributions to impaired healing and development of complication. Here we
show for the first time that fungal communities (the mycobiome) in chronic wounds are
predictive of healing time, associated with poor outcomes, and form mixed fungal-bacterial
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biofilms. We longitudinally profiled 100, non-healing diabetic foot ulcers with high-throughput
sequencing of the pan-fungal internal transcribed spacer 1 (ITS1) locus, estimating that up to 80%
of wounds contain fungi, whereas cultures performed in parallel captured only 5% of colonized
wounds. The ‘mycobiome’ was highly heterogeneous over time and between subjects. Fungal
diversity increased with antibiotic administration and onset of a clinical complication. Proportions
of the phlyum Ascomycota were significantly greater (p=0.015) at the study onset in wounds that
took >8 weeks to heal. Wound necrosis was distinctly associated with pathogenic fungal species,
while taxa identified as allergenic filamentous fungi, were associated with low levels of systemic
inflammation. Directed culturing of wounds stably colonized by pathogens revealed that interkingdom biofilms formed between yeast and co-isolated bacteria. Combined, our analyses
provide enhanced resolution of the mycobiome during impaired wound healing, its role in chronic
disease, and impact on clinical outcomes.

3.3 Importance
Wounds are an under-appreciated but serious complication for a diverse spectrum of
diseases. High-risk groups, such as persons with diabetes, have a 25% lifetime risk of developing
a wound that can become chronic. The majority of microbiome research related to chronic
wounds is focused on bacteria but the association of fungi with clinical outcomes remains to be
elucidated. Here we describe the dynamic fungal communities in 100 patients with diabetic foot
ulcers. We found that communities are unstable over time, but at the first clinical presentation, the
relative proportions of different phyla predict healing times. Pathogenic fungi not identified by
culture reside in necrotic wounds, and are associated with poor prognosis. In wounds stably
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colonized by fungi, we identified yeast capable of forming biofilms in concert with bacteria. Our
findings illuminate the associations of the fungal mycobiome with wound prognosis and healing.

3.4 Introduction
In recent years, the implication of microorganisms in complex human processes has
begun to come into focus. Negative consequences of these interactions can result in large healthcare burdens such as non-healing or chronic wounds (1-5). One example is diabetic foot ulcers
(DFUs), which contribute to 80% of non-traumatic lower-extremity amputations and are
associated with five-year mortality rates of 43-55%, higher than Hodgkin’s disease, breast cancer
or prostate cancer(6-8). Chronic wounds are largely believed to be critically colonized by
polymicrobial communities that contribute to persistent inflammation and stalled healing
processes, significantly reducing the quality of life for those inflicted(9-11). The skin normally
harbors diverse communities of microbes(12-17) that can contribute to health, but like other
ecosystems, the niche can direct composition and ultimately function(18-20). In tissue injury,
microbes enter the wound where the physical environment differs from the skin surface in
temperature, pH, nutrient availability, and host immune effectors. Here, microbial metabolism
can shift, providing opportunities for commensal microbes to become virulent and community
compositions to fluctuate in response to host clinical factors(21-23). It is hypothesized that once
colonization occurs these communities form a biofilm within the wound, disrupting the
coordinated tissue regeneration process. This is also true in other chronic infections, such as
cystic fibrosis (CF) where the environment of the CF lung allows for colonization(24), unlike the
healthy lung from which microbes can be cleared .
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Prior research has primarily focused on the role of bacterial species in wound healing(10,
23, 25-30); however, the skin is also host to resident fungi and our environment is rich with
fungal diversity(31-34). Many human commensal fungi or yeast are also opportunistic pathogens,
and many species are known to be prolific biofilm formers(34-38). There are few studies
describing the ‘mycobiome’ portion of the human microbiome and it’s relation to health(32, 34,
39-41), while the incidence of fungal colonization in chronic wounds is even less known. A
previous cross-sectional study of chronic wounds of mixed etiology and without standardized
treatment utilized molecular-based methods to observe that up to 23% of chronic wounds contain
fungi (41). Chellan et al. studied 518 diabetic lower leg wounds and detected fungi in 27% of
samples with culture-based methodology(42). In these studies, several aspects of the crosssectional study design limit the ability to draw conclusions. These designs preclude longitudinal
observation of fungal colonization, and the relationship to clinical outcomes (i.e. rate of healing,
infection-related complication), while controlling for clinical variables such as tissue perfusion or
blood glucose control.

Here, we add a new perspective to the current models of impaired wound healing with a
longitudinal study of 100 DFUs under standardized treatment. High-throughput sequencing of the
nuclear ribosomal internal transcribed spacer 1 (ITS1) allowed us to define the dynamic diversity
of the mycobiome, its stability in response to host factors, and the association of pathogenic fungi
with poor clinical outcomes.
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3.5 Results
3.5.1 Study overview
To minimize variability associated with wound etiology, we limited our study to a single
wound etiology consisting solely of DFUs. Subjects were enrolled into the study and wound
specimens were obtained every two weeks until the wounds healed, another infection occurred,
the wounds resulted in amputation, or were not closed after 26 weeks (Visit 0 -12). Table 1
summarizes the cohort where a total of 384 specimens were collected from 100 DFUs in a sample
of 100 subjects. Additional clinical factors measured include white blood cell count (WBC),
ankle-brachial index (ABI), toe-brachial index (TBPI), hemoglobin A1c, glucose (HgbA1c), C
Reactive Protein, and transcutaneous oxygen levels of the wound edge. Monofilament testing
confirmed neuropathy in all subjects. Complications were experienced by 31 (31%) subjects
defined as: 1) wound deterioration, 2) development of osteomyelitis, and/or 3) amputations.

The fungal component of DFU microbiomes was studied by sequencing the
hypervariable internal transcribed spacer 1 (ITS1) region of the eukaryotic ribosomal RNA
cistron using the Illumina MiSeq platform (2x300 PE chemistry). The ITS region has been
formally recognized as the universal barcode for fungal identification(43) so we elected to use
this region and the curated fungal barcode reference database UNITE(44) for operational
taxonomic unit (OTU) assignment. We employed the PIPITS pipeline(45) because it extracts the
ITS sub-region from raw reads and assigns taxonomy with a trained RDP Classifier(46). Of the
10,673,363 sequences, 10,593,779 sequences were identified as containing an ITS1 subregion.
DNA from Saccharomyces cerevisiae was detected in the medium in which the wound samples
were collected, and therefore all OTUs identified at the genus or species level as Saccharomyces
were filtered from the data set, resulting in removal of 3 phylotypes. After quality filtering and
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contaminant removal, 2,842,822 reads remained, resulting in 482 OTUs and taxonomic
identification yielded 284 phylotypes.

3.5.2 Characterization of the DFU Fungal Mycobiome
Seventeen phylotypes were identified in >1% relative abundance across the entire dataset,
all belonging to the phyla Ascomycota or Basidiomycota. The two most abundant taxa were
Ascomycota corresponding to Cladosporidium herbarum (teleomorph Davidiella tassiania),
present in 41% of the samples and 56% of subjects, followed by Candida albicans (22% of
samples; 47% of subjects). Notably, 10 of the 17 most abundant taxa are Ascomycetes
filamentous fungi found ubiquitously in the environment, while the most abundant
Basidiomycota identified were opportunistic yeast pathogens Trichosporon and Rhodosporidium
spp. (Table 2, Figure 1A).

Malassezia species are reported as a major component of the healthy skin
mycobiome(32) and were detected in >0.05% abundance in 26 subjects in a total of 36
specimens, but only seven specimens had >10% relative abundance of Malassezia species. This
observation is not unexpected as Malassezia spp. are lipid dependent and the foot is known to
have overall lower abundances of Malassezia spp. relative to other body site niches(32, 47), in
part due to absence of sebum in this microenvironment and in the wound itself.

A major current limitation of molecular DNA sequencing based analysis of the
mycobiota is representation of fungal species in available reference databases. It is estimated that
sequence data is available for a mere 1.5% of the estimated 1.5 million fungal species(46).
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Indeed, 32% of the DFU samples contained OTUs that could not be assigned beyond the kingdom
level and 16% of samples contained OTUs unclassified beyond phylum Ascomycota (Table 2).
Limitations of reference databases necessitate the use of reference-independent analyses to
characterize diversity and variation of fungal communities. Alpha diversity metrics use referenceindependent OTU data to summarize diversity, such as number of OTUs in a sample and their
evenness. We analyzed DFU mycobiome alpha diversity with respect to wound health and
inflammation factors measured at the patient- and ulcer-level (Supplementary Figure 1 and
Supplementary Table 1). At baseline, diversity measured as the number of observed species-level
OTUs (median=6; range=1-21) and Faith’s PD (median=4.64; range=1.31-14.92) was negatively
associated with tissue oxygenation (rho=-0.258, p=0.046; rho=-0.295, p=0.022, respectively)
(Supplementary Figure 1), suggesting that high fungal diversity is associated with poor perfusion.
As measured by the Shannon Diversity Index, which takes into account both richness and
evenness of OTUs, ulcers on the forefoot were more diverse (median=1.03; range=0-3.83)
compared to hindfoot ulcers (median=0.51; range=0-1.65; Wilcoxon rank sum test; p=0.02) with
midfoot ulcers falling in between (median=0.95; range=0-3.15) to create a gradient of diversity
(Figure 1B). The number of observed species-level OTUs did not significantly differ between the
forefoot and hindfoot indicating that evenness of differentially abundant OTUs contribute to
topographical variability of the mycobiome. Decreased Shannon Diversity appears to be primarily
driven by a significant increase in the relative abundance of C. albicans in ulcers formed on the
hindfoot (Figure 1C; Supplementary Table 2).

At each study visit, wound specimens were also collected for quantitative cultures. Three
subjects were culture positive for yeast isolates categorized as “skin flora” or “other” and two
subjects were positive for Candida sp. at one study visit. In all five cases, the study visit positive
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for yeast culture was concurrent with or preceded the study visit of a complication
(Supplementary Figure 2). With a culture-independent sequence-based approach, after quality and
contaminant filtering, 275 of the 384 samples analyzed, corresponding to 79 subjects, were
positive for at least one fungal phylotype (Table 1). The culture positive specimens were
confirmed by ITS1 sequencing to contain high relative abundances of Candida spp (C. albicans,
C. glabrata) with the exception of one subject specimen containing primarily Trichosporon
asahii. Our analysis identified these same species and others in additional study visits
(Supplementary Figure 2). For these subjects, we also compared the bacterial communities
(obtained by 16S rRNA gene sequencing and reported in(48)) and discovered in some cases, such
as subject 194 and 198 (visit 0), fungal identification resulted in the absence of bacterial taxa in
the specimen. However, for the majority of wound specimens, mixed fungal-bacterial
communities were observed (Supplementary Figures 2,3A).

3.5.3 The DFU Mycobiome Has High Interpersonal and Intrapersonal Variation
A striking feature of DFU fungal community structures was the absence of a core
mycobiome or shared taxa across the study cohort (Figure 1A). We assessed the temporal
stability of fungal communities over time by calculating the weighted UniFrac distances (WUF)
between study visits within a single subject. We compared this to mean interpersonal WUF
distances at their baseline visit. Mean interpersonal WUF distances were significantly greater
than mean intrapersonal WUF distances (Figure 1D), suggesting that interpersonal variability is
greater than intrapersonal variability. However, a high level of dissimilarity occurred in both
groups (mean = 0.71 vs 0.67, respectively; Wilcoxon rank sum test; p<0.0001). At the taxonomic
level, community structure was ephemeral, with taxa sometimes appearing or disappearing within
one study visit (Figure 2).
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High rates of change between study visits suggest transient colonization or environmental
contamination of the wound bed by fungi. Contrary to this hypothesis is the standardized care
employed in this study, where a total contact cast (TCC) (n=87) or a DH Boot (n=13) was applied
for offloading following wound cleansing and dressing. TCC results in creation of an occlusive
environment for the entire foot, minimizing influence from the external environment. We
examined the mycobiome community stability of ulcers offloaded with TCC and DH Boot, but
did not observe significant differences between the two offloading methods (data not shown).

3.5.4 The DFU Mycobiome is Associated with Clinical Outcomes
We next determined if the DFU mycobiome was associated with clinical outcomes. An
ideal biomarker would differentiate wound outcomes at initial patient presentation; therefore, we
analyzed the mycobiomes of the baseline study visit (Visit 0) with respect to outcomes, in
addition to analyses incorporating all longitudinal data. At the baseline study visit, Ascomycota
were present in significantly greater relative abundance in wounds that healed in >8 weeks
compared to those that healed in <4 weeks (Tukey post-hoc; p=0.017). This distribution was only
significant at the initial presentation and did not significantly differ by healing time of all the later
visits combined (Figure 3A). Baseline specimens were taken at the initial clinical presentation
and before the wound was surgically debrided of dead tissue and/or biofilms, but the specimens
were obtained over viable wound tissue, not necrotic tissue. This suggests that the mycobiome at
the presentation visit can be predictive of time to heal.

We also assessed stability of the mycobiome and its association with outcomes. Intervisit WUF was not associated with healing outcome; healed, unhealed or amputated wounds
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display high levels of change over time that were not significantly influenced by a clinical
complication or administration of an antibiotic (Figure 3B, C). Although the mean WUF values
were >0.5, indicating high rates of change, in some cases, a trend was observed in subjects that
ultimately required an amputation, where the WUF values were lower, meaning mycobiomes
from sequential visits were less dissimilar. This suggests a more stable colonization of the fungal
community, and potentially implicates the formation of a biofilm or infection leading to
subsequent chronicity. This is exemplified in the bottom panel of Figure 2 (subject 198) where
the first three study visits of this particular subject were dominated by Trichosporon asahii
followed by a shift to a predominant population of C. herbarum in the later visits. Conversely, the
bacterial community stability in this subject is low during the first three visits, until the fungal
community shifts and stability for both groups then follows the same general pattern. Similar
trends are observed in other subjects and indicates that the stability of the fungal community
structure is not independent from co-habitating bacterial community stability (Supplementary
figure 3B).

Antibiotics were administered to 31 of 100 subjects at some point during the course of
the study. We hypothesized that antibiotic treatment would influence the fungal portion of the
microbiome in response to observed bacterial perturbation and disruption (48). In subjects that
received antibiotics, the Shannon diversity indices for all visits combined were significantly
higher than those subjects who did not receive an antibiotic (Wilcoxon rank sum test; p=0.029).
However, diversity over time did not significantly fluctuate before, during or after antibiotic
administration. We also examined the class of antibiotic administered and discovered it was nondiscriminating in influencing the overall diversity metrics in these subjects (Supplementary
Figure 4). In samples from study visits where a complication occurred, Shannon diversity was
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also significantly higher (mean=0.98 vs 1.30; Wilcoxon rank sum test; p<0.001) but visits with
complications only co-occurred with visits of antibiotic administration 45% of the time (41/91
total visits).

3.5.5 Pathogens versus allergens in the DFU mycobiome
We elected to bin taxa into the categories “pathogens” or “allergens”, because with
respect to the skin and cutaneous infection, the majority of taxa identified in our dataset fell into
one of these two groups of either known/opportunistic skin pathogens or the filamentous fungi
often identified as allergenic molds (Figure 4A). While some members of the “allergens” group,
such as Aspergillus spp., can also be opportunistic pathogens, this is rare in the context of skin
and cutaneous infection so we limited their classification. We first assessed associations between
the list of allergen and pathogen phylotypes and the taxa listed in Table 2 using Spearman rank
correlations. Taxa correlations were then subjected to hierarchical clustering via hclust. The
allergens and pathogens clustered separately, discriminated by their associations with six key taxa
(Aspergillus cibarius, Penicillium bialowiezense, Epicoccum nigrum, Pencillium sp.,
Trichopsoron asahii and Candida albicans). Allergens had positive associations with all six,
whereas pathogens did not exhibit any strong associations, positive or negative. (Supplementary
Figure 5).

With respect to clinical outcomes, a trend emerged where the mean proportions of
pathogens were higher in non-healing wounds and those that ultimately resulted in amputation, as
compared to wounds that healed, though this trend was not statistically significant (Figure 4B).
The mean proportion of allergens was unchanged across all outcome groups (data not shown).
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We also examined mean relative abundance of allergens and pathogens with respect to necrosis,
because the level of necrotic wound tissue may indicate wound health or deterioration. Strikingly,
in wounds with 75-100% necrotic tissue the proportion of allergens is reduced and a highly
significant increase in the proportions of pathogens is observed (p<0.001; analysis of variance
and Tukey post-hoc analysis) (Figure 4C). To better visualize this distribution across samples, we
constructed an independently calculated weighted UniFrac distance ordination plot overlaid with
the relative proportion of allergens, pathogens and the level of necrotic tissue in each sample.
Clear separation is observed between the two groups and pathogens are predominantly found in
those samples with high levels of necrosis (Figure 4D).

Since pathogens may directly contribute to wound necrosis and negative outcomes, the
most severe being amputation, we further examined all possible associations between additional
clinical factors and the relative abundance of pathogens and allergens, and the two dominant taxa
in each of those groups (C. albicans and C. herbarum respectively). By Spearman rank
correlation, allergens were negatively associated with HgbA1c levels (rho=-0.308, p=0.02) and
WBC counts (rho=-0.346, p=0.009), suggesting that glucose control and lower levels of
inflammation are consistent with allergen colonization (Supplementary Figure 1). Specifically, C.
herbarum was negatively associated with HgbA1c (rho=-0.405, p=0.002) but positively
associated with the ulcer surface area (rho=0.348, p=0.008) and days in the study (rho=0.279,
p=0.038) (Supplementary Figure 1). Because the culture positive samples co-coincided with
wound deterioration and the mean proportion of the group “pathogens” is elevated in non-healing
wounds and necrosis, we looked for associations between both Candida spp. and the pathogens
group to clinical factors but no additional significant associations were identified (Supplementary
Figure 1).
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3.5.6 The DFU Mycobiome Forms Multi-Species Biofilms with Bacteria
We hypothesized that biofilm formation occurred in those ulcers where a pathogenic
fungal species was detected. Cultures were obtained from samples collected from subjects 145
and 198, representing delayed (>6 weeks) but healed and amputated wounds, respectively (Figure
2). C. albicans was isolated from subject 145 and T. asahii from subject 198. Samples from these
subjects also grew the bacterial isolates Citrobacter freundii (subject 145) and Staphylococcus
simulans (subject 198). The ability for each isolate to form a biofilm as mono-culture or coculture was assessed and confirmed visually by confocal microscopy. The yeast-bacteria pairs (C.
albicans + C. freundii; T. asahii + S. simulans) readily grew as co-culture on agar plates. Biofilm
growth was observed for mono-culture of each yeast strain with distinct hyphal growth of C.
albicans and chains or clumping of cells for T. asahii. The bacterial strains were also able to grow
as biofilms in mono-culture, forming distinct micro-colonies although in a more dispersed and
confluent layer than the yeast mono-cultures (Figure 5). Mixed-species biofilms formed within 24
hours and further matured over 48 hours. The co-cultures revealed close interactions between
bacterial and yeast cells. The yeast appears to form the ‘core’ of the colony and bacteria associate
around the periphery of the cells, coating yeast cells and hyphae as they grow out of the plate to
approximately 30 µM thick for C. albicans + C. freundii and 15 µM thick for T. asahii and S.
simulans after 48 hours (Figure 5). These observations coupled with quantitative counts of the
planktonic and biofilm mono- or co-cultures (Supplementary Figure 7) suggest that the yeast and
bacterial species interact in a non-competitive manner to form mixed biofilms.

To assess fungal-bacterial interactions with a more global view we determined Spearman
rank-correlations between the fungal and bacterial taxa found in >1 % abundance in the entire
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dataset. Corynebacterium sp. in the order Actinomycetales, was significantly negative correlated
with C. albicans and C. parapsilosis. Members of the Actinomycetales are historically rich
sources of bioactive small molecules. On the other hand, C. albicans was significantly positively
correlated with the order Alcaligenaceae, a group of Gram-negative Proteobacteria.

3.6 Discussion
Chronic non-healing wounds are host to polymicrobial communities that can form
biofilms and interfere with healing processes. Here we utilized high-throughput sequencing of the
ribosomal RNA internal transcribed spacer ITS1 amplified from DFU specimens collected
longitudinally to demonstrate that DFUs contain a diverse repertoire of fungi not recognized
clinically or by traditional culture procedures. Our study is the first to identify fungi in a large
proportion (80%) of DFUs surveyed. The longitudinal aspect of our study design and
standardized care protocol establishes that the mycobiome is highly dynamic and transient in
DFUs, with increased fungal diversity in subjects administered antibiotics or experiencing a
complication. While the subset of subjects on antibiotics was not large enough to allow for
detailed investigation into the short- and long-term effects on the mycobiome, future studies are
warranted, incorporating both fungal and bacterial community dynamics in response to antibiotic
perturbation.

Studies of the mycobiome in chronic disease are not abundant. It was striking to us that
C. herbarum was the most abundant species found in ≥1 sample from 56% of our subjects.
Although this saprophytic dematiaceous fungus is widespread in the environment, it has been
reported as one of the most common fungal species associated with the human body across
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different body sites including the oral, nasal, vaginal and gut mycobiomes(31, 34, 49-51). Not
only are Cladosporium spp. sensitizing agents leading to allergic rhinitis, but they are linked to
other human diseases including an outbreak of fungal meningitis in 2012(52), and recently
Cladosporium spp. were identified in 92 clinical specimens with 28% of those coming from
superficial and deep tissues(53). Together, these data indicate that Cladosporium spp. should be
regarded as a member of the human mycobiome.

Candida albicans was the second most abundant phylotype identified, present in 47
subjects and 21% of samples. Other species identified were C. parasilopsis (15%), C. tropicalis
(9.76%), C. glabrata (3.7%), and C. smithsonii (2.9%), while C. boleticola, C. dubliniensis, C.
orthopsilosis, C. metapsilosis, and C. xylopsoci were found in less than 3% of the samples.
Candida abundance can fluctuate during gut microbiome dysbiosis, for instance by antibiotic
administration early in life, and has been associated with asthma and allergic airway response to
fungal allergens(54-56). Specifically, overgrowth of Candida albicans in the gut microbiome of
mice can provoke sensitization resulting in a CD4+ T-cell mediated response to mold spores that
is not observed in mice without microbiota disruption(57). It is not clear if similar responses
occur in other tissues and body sites, or if this response is isolated to the gut-airway axis. The
DFU mycobiome is primarily composed of a balance of commensal and pathogenic yeasts
(Candida spp, Trichosporon spp.) and a heterogeneous population of anamorphic fungi
recognized as important causes of respiratory allergies(58). Instability in communities both interand intra-individually suggests transient or superficial colonization of the DFUs by spores,
highlighting an important limitation to sequence based studies: the inability to determine active
metabolism. In this context however, it is tempting to imagine a scenario by which exposure to
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fungal spores and their antigens is sufficient to provoke an immunological response that
contributes to prolonged inflammation and stalled healing.

Poor perfusion is a hallmark of DFUs and can contribute to impaired healing. Increased
fungal diversity in DFUs with reduced oxygenation is consistent with our finding that biofilm
forming yeasts and opportunistic skin commensal pathogens were highly significantly and
strongly associated with wound necrosis and poor outcomes. This association was not driven by a
single species but a mixed group of pathogens.

This study provides the foundation for further dissection of microbial interactions and
their profound influence on disease progression. Here, we demonstrate the ability of DFU isolated
yeast-bacterial pairs to form mixed biofilms. Two pairs were cultured from DFUs identified as
having a stable community by our molecular analysis and used to validate fungi-bacteria biofilm
formation. To our knowledge there is little information regarding interactions between C.
albicans and C. freundii or T. asahii and S. simulans. Our in silico analysis also suggests that an
antagonistic interaction is occurring between Candida sp. and Corynebacterium sp. Continued
exploration to determine the magnitude and mechanisms of microbiome interactions in
contributing to impaired healing and skin and soft tissue infection is an important and timely area
of research. Observation of diverse fungal communities in chronic non-healing wounds and their
ability to form inter-kingdom biofilms with both Gram-negative and Gram-positive bacterial
species emphasizes the paramount importance but also complexity of studying whole microbial
communities, their inter-species interactions and implications in chronic disease.
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3.7 Materials and Methods
3.7.1 Study Design
During September 2008 through October 2012 100 subjects were enrolled in a
prospective-cohort to sample the DFU microbiota and measure outcomes. Subjects were recruited
through local media advertisements and from outpatient clinics at the University of Iowa
Hospitals and Clinics (UIHC) and the Iowa City Veteran’s Affairs Medical Center (VA). Samples
for microbiota analyses were collected at initial presentation (V0) and every two weeks until the
DFU: i) healed; ii) was amputated; or iii) 26 week of follow up elapsed (V1-12). The Institutional
Review Boards at the University of Iowa (IRB#200706724) and the University of Pennsylvania
approved the study procedures (IRB#815195). Informed consent was obtained from all
participants in writing.

Wound management was standardized to aggressive sharp debridement of necrotic tissue
in the wound bed at baseline and wound edge callus removal every two weeks followed by nonantimicrobial dressing application (i.e., Lyofoam®, Molnlycke Health Care). Ulcers were
offloaded with total contact casts (87 subjects) or DH boots (13 subjects). Topical antimicrobial
or system antibiotic administration was not included unless an infection-related complication was
present at baseline or occurred within the study period. Data was collected at baseline and
longitudinally every two weeks until the wound healed or 26 weeks elapsed.

3.7.2 Study Variables
Clinical factors: Demographic variables were collected at the baseline visit including
age, sex, diabetes type and duration and duration of the study ulcer using subject self-report and
medical records. At each study visit glycemic control was measured by levels of haemoglobin
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A1c and blood glucose. Inflammatory (Erythrocyte sedimentation rate (ESR), C-reactive protein)
and immune (white blood cell counts) markers were determined with standard laboratory tests.
Each subject was also assessed for ischemia using the ankle-brachial and toe-brachial index and
for neuropathy using the 5.07 Semmes-Weinstein monofilament test. Transcutaneous oxygen
pressure was measured at baseline and at each follow-up visit, using a transcutaneous oxygen
monitor (Novametrix 840®, Novametrix Medical Systems Inc.). Ulcer location was categorized
as forefoot, midfoot, or hindfoot. The level of necrotic tissue was defined as black, grey or
yellow tissue in the wound bed measured using a likert scale as the percentage of the total wound
area binned according to 0-25%, 25-50%, 50-75% or 75-100% necrotic tissue.

Outcomes: Healing and infection-related complications were assessed every two weeks.
Ulcer closure was determined using the Wound Healing Society’s definition of “an acceptably
healed wound,” a valid and reliable definition(59). “Development of infection-related
complications” was defined as wound deterioration, new osteomyelitis, and/or amputations due to
DFU infections.

Wound deterioration was defined as the new development of frank erythema and heat,
and an increase in size > 50% over baseline. Two members of the research team independently
assessed each DFU for erythema and heat. Two members of the research team independently
assessed size using the VeVMD® digital software system (Vista Medical, Winnipeg, Manitoba,
Canada) and procedures previously described(60). A cotton-tipped swab, placed in the deepest
aspect of the DFU, was marked where the swab intersected with the plane of the peri-wound skin.
The distance between the tip of the swab and the mark was measured as ulcer depth using a
centimeter ruler.
71

Osteomyelitis was assessed using radiographs and MRI at baseline and during follow-up
visits when subjects presented with new tracts to bone, wound deterioration, elevated
temperature, elevated white count, elevated erythrocyte sedimentation rate, or elevated C-reactive
protein. If these indicators were absent at follow-up, radiographs were not retaken. Subjects
experiencing new amputations had their medical records reviewed by the research team to ensure
amputations were due to DFU infection, and not some other reason.

Sequencing of fungal ITS1 rRNA region: Ulcer specimens were collected using the
Levine technique and established protocols(61). DNA was isolated from swab specimens as
previously described(21). The ITS1F (CTTGGTCATTTAGAGGAAGTAA) and ITS2R
(GCTGCGTTCTTCATCGATGC) primers were used for PCR amplification, each having a
linker sequence, a sample specific GoLay12 index, and an Illumina adapter to amplify the ITS1
region of the fungal rRNA region. These indexed primers were used in combinations that made it
possible to multiplex up to 576 (24 x 24) samples at a time. Each sample (along with one mock
community, three buffer controls and two water controls) was amplified in duplicate, combined,
and cleaned using the Agencourt AMPure XP bead-based PCR purification system (BeckmanCoulter). PCR reactions contained 9.65 µL PCR-clean water, 1.25 µL 10X Accuprime Buffer II
(Invitrogen), 0.1 µL Accuprime High Fidelity Taq (Invitrogen), 0.25 µL each of the forward and
reverse primers (at 10 µM concentration), and 1.0 µL genomic DNA. Reactions were held at
94°C for 3 min to denature the DNA, with amplification proceeding for 35 cycles at 94°C for 45
s, 56°C for 60 s, and 72°C for 90 s; a final extension of 10 min at 72°C was performed. Purified
amplicon pools were quantified using the Quant-IT dsDNA High-Sensitivity Assay Kit
(Invitrogen) and a microplate reader (Thermo Scientific). A composite sample for sequencing
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was made by combining equimolar ratios of amplicons from the samples, followed by gel
purification with a Qiagen MinElute Gel Extraction Kit to remove potential contaminants and
PCR artifacts (the acceptable size window for amplicons was 200-1000 bp in length). The pooled
DNA was quantified using a Qubit Fluorometer (Life Technologies), and PhiX174 genomic DNA
was spiked in to the sample at ~40% prior to sequencing. MiSeq 300 bp paired-end ‘V3’
sequencing was performed. Additional negative controls were processed as above, except the
ITS1F and ITS2R primers were used without barcoded adapters and amplicons were sequenced
by standard Sanger sequencing.

The MiSeq ITS libraries were preprocessed using an in-house pipeline that includes read QC,
barcode de-multiplexing, paired-end assembly and linker cleaning steps. The pipeline procedures
are briefly explained below.
1. Read QC. Raw read quality was checked for the average and range of the Phred quality
scores along the reads (1~300 bp) for both forward and reverse reads independently.
2. Read de-multiplexing. Our MiSeq ITS library construction protocol utilizes a customized
barcode system with both forward & reverse barcodes embedded near the 5’ of both reads;
thus, the forward and reverse barcodes are first spliced and concatenated from the
corresponding reads, then read-pairs are de-multiplexed using the Flexbar program (v2.4)(62)
with default settings.
3. Paired-end assembly. De-multiplexed paired-end reads are assembled (merged) using the
PEAR (v0.9.0) program(63) with default settings.
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4. Barcode/linker cleaning. Our customized barcode/primer system incorporates a linker region
between the actual barcodes and PCR primers to increase the heterogeneity of the amplicons
for successful Illumina sequencing. These in-line barcode and linker sequences are cleaned
from final assembled amplicons by in-house Perl scripts, in a way that is based only on the
length of the barcodes/linkers, which guarantees a successful removal.
The PIPITS pipeline was used for ITS1 processing(45). Briefly, the ITS1 region was
extracted with ITSx(46), clustered into operational taxonomic unites (OTUs) with
VSEARCH(https://github.com/torognes/vsearch) at 97% sequence similarity and chimera
removal performed using the UNITE UCHIME reference data set. Representative sequences were
assigned taxonomic classification with the RDP classifier against the UNITE fungal ITS
reference data set(64) at a confidence threshold of 0.85. Contaminants found in negative controls
(corresponding to taxa Saccharomyces cereviseae or Alternaria eichornia) were removed at the
OTU level (4 OTU’s removed) followed by subsampling 500 sequences per sample. The Shannon
diversity index, Simpson diversity index (1-D), Faith’s phylogenetic distance (PD) and number of
observed species (richness) were calculated using the QIIME 1.8.0 alpha_diversity.py script(65).
Beta-diversity metrics were calculated with the QIIME 1.8.0 beta_diversity.py script.

3.7.3 Fungal and Bacterial Manipulation
Isolation: Yeast and bacterial isolates were grown from wound swabs collated in
trypticase soy broth (TSB). Briefly, 100 µL of TSB containing the swab was plated onto yeastmold (YM; Neogen, Lansing, MI) and incubated at 25°C for up to 7 days. Individual colonies
were picked and grown on YM or TSB agar plates to be made into glycerol stocks for long term
storage. All strains isolated were identified by amplification of the ITS1 region (primers
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described above without adapters) or 16S rRNA gene (16S 27’F and 534’R) and Sanger
sequencing. Secondary confirmation was obtained by MALDI TOF mass spectrometry at the
Pennsylvania Animal Diagnostic Laboratory System.

The yeast isolate grown from P198 was identified as Trichosporon asahii by Sanger
sequencing and a BLAST search against the NCBI nt database and UNITE database. The
sequence was compared to the OTU identified as Trichosporon ovoides as part of the PIPITS
pipeline and found to have 100% identity so the OTU was re-classified as T. asahii.

Biofilm growth: Isolates were grown overnight at 37°C on YM agar (fungi) or TSA
(bacteria). Colonies were scraped into 0.89% NaCl to an OD600 nm of 0.08-0.1 with the exception
of T. asahii (OD600nm =0.17-0.2). Bacterial suspensions were diluted 1/10 into RPMI 1649,
GlutaMax media (ThermoFisher Scientific, Waltham, MA). The inoculums were then added in a
1/10 dilution to a final volume of 4 mL RPMI in 35 mm polystyrene plates. Cultures were
incubated stationary at 37°C for 24 or 48 hrs to allow adhesion and growth. The media was
removed and the biofilms washed with 2 x 1 mL sterile 0.89% NaCl to remove non-adherent
cells. The biofilms were stained with the LIVE BacLight Bacterial Gram Stain Kit (ThermoFisher
Scientific, Waltham, MA) with SYTO9 (480nm/500nm) and hexidium iodide (480nm/625nm) as
a 2 mL solution in water and according to the kit instructions. The stain was removed and
deionized water was added to the biofilms prior to imaging on a Leica TCS SP5 microscope with
20x objective. Images were post-processed with Volocity software (PerkinElmer, Waltham, MA,
USA). The maximum projection for each image was used to generate figure 5.
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Quantitative counts of mono and co-cultures were performed by serial dilution of
planktonic cells (media), wash media (2 x 1mL) and 0.89% saline containing adherent cells that
were scraped and resuspended (n=2). The dilutions were plated onto non-selective media (YM or
TSA) and incubated for 16-18 hrs at 37°C. Colonies were counted and the total CFUs calculated.

3.7.4 Data Analyses
The R Statistical Package (66) was used for all computations unless described elsewhere. The
classification of ‘Pathogens’ or ‘Allergens’ was performed manually based on classification in
literature. Statistical methods are described within the text and figure legends. Correlations
between microbiome and clinical features were determined by calculating the Spearman
coefficient.

3.8 Data Availability
All sequence data is publicly available on the NCBI Sequence Read Archive with accession
number SRP076355 and BioProject Accession number PRJNA324668.
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3.11 Figures

Figure 1
The DFU mycobiome is diverse and highly heterogeneous. A) Heatmap of fungal community
structure for all subjects at the baseline study visit. Hierarchical clustering was performed for taxa
found in >20% abundance in at least one sample. B) Boxplot showing the Shannon diversity
index (Y-axis) by wound location (X-axis). P-values were calculated by pairwise Wilcoxon rank
sum test and adjusted for multiple comparison by method of Holm. C) Relative abundance plot
showing the mean proportions of taxa found in >1% abundance in all of the samples (Y-axis) by
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wound location (X-axis). Taxa found in significantly different abundance between forefoot and
hindfoot wounds are listed in Table S2. D) Boxplot showing the weighted UniFrac distances (Yaxis) between subjects (baseline study visit only) and within subjects longitudinally (X-axis). The
P-value was calculated by Wilcoxon rank sum test. Notches in boxplots display the 95%
confidence interval around the median.
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Figure 2
The DFU mycobiome is temporally unstable. Five individual subject timelines showing the
relative abundance and structure of fungal communities for DFUs that healed, did not heal within
the 26 weeks of the study, or resulted in an amputation. Numbers on the X-axis represent study
visit number and Y-axis represents proportion of taxa present.
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Figure 3
The DFU mycobiome is associated with clinical outcomes. A) Relative distribution of
Ascomycota and Basidiomycota in specimens grouped by time to heal. Baseline specimens (left
panel) were taken from viable wound tissue prior to sharp debridement and cleansing. All study
visits after the baseline study visit are combined (right panel). P-values are calculated with an
analysis of variance model and post-hoc Tukey HSD multiple comparison of means. B) A
boxplot showing inter-visit weighted UniFrac distances (Y-axis) by end of study reason (X-axis)
were not significantly different. Notches display the 95% confidence interval around the median.
C) A timeline of weighted UniFrac distances (Y-axis) plotted by study visit (X-axis) for
individual subjects and grouped by end of study reason (top panel = healed; middle panel =
unhealed after 26 weeks of follow-up; bottom panel = amputated). Blue dots indicate that a
complication was recorded at the study visit. Triangles indicate study visit at which an antibiotic
was administered at or within the previous two-weeks.
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Figure 4
Pathogens are associated with necrotic tissue and poor outcomes. A) Mean proportion (%) (Xaxis) of pathogen (Y-axis;left panel) and allergen (Y-axis, right panel) taxa in the data set. B)
Mean proportion of pathogens (Y-axis) by end of study reason (X-axis). Error bars indicate
standard error of the mean. C) Mean proportion of pathogens, allergens, unclassified Fungi, and
unclassified Ascomycota in samples grouped by the level of necrotic tissue present in the wound.
The level of pathogens is significantly higher in ulcers with >75% necrotic tissue compared to all
other levels of necrosis. P-values are calculated with an analysis of variance model and post-hoc
Tukey HSD multiple comparison of means. D) Principal coordinate plot comparing samples by
the weighted UniFrac distance. Percent variation explained by each principle coordinate is
indicated by % next to each axis. Point size indicates necrotic tissue level, with larger points
corresponding to greater amounts of necrotic tissue in the wound from which the sample was
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taken. The proportions of allergens and pathogens was calculated by subtracting the proportion of
pathogens from the proportion of allergens in each sample resulting in a scale of -1 (dominated by
pathogens) to +1 (dominated by allergens). A value of zero indicates either zero or equal
proportions of each.
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Figure 5
Pathogens form inter-kingdom biofilms. Fluorescent confocal microscope images of mono- or coculture Candida albicans and Citrobacter freundii or Trichosporon asahii and Staphlococcus
simulans. Biofilms were grown for 48 hrs. at 37ºC on polystyrene plates in RPMI 1649,
GlutaMax media, washed to remove planktonic cells and stained with SYTO 9 and hexidium
iodide (HI) prior to imaging. Fungi (large) and bacteria (small) can be distinguished by size.
Fungi appear green and bacteria red in the merged images. The size of the scale bar for each row
is labelled in the first column (SYTO 9) for each culture. The insets are zoomed in portions of the
merged co-culture biofilm images.
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Figure S1
Heatmap illustrating positive (yellow) and negative (purple) correlations between microbiome
factors and clinical factors at baseline. Correlations were calculated by the Spearman correlation
coefficient. Significant correlations are marked with an asterisk (p=<0.05) and rho and p-values
are summarized in Table S1.
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Figure S2
Subjects with positive yeast culture result. The study visit that was culture positive is marked by
(*) and the identified species are labelled. Relative abundance plots are shown for taxa identified
by ITS1 analysis and found in >5 % abundance in each sample. Numbers on the X-axis represent
study visit number and Y-axis represents proportion of taxa.
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Figure S3
Subjects with positive yeast culture result. A) Relative abundance plots are shown for bacterial
taxa identified by 16S rRNA gene analysis and found in >1 % abundance in the entire dataset
(384 samples). Numbers on the X-axis represent study visit number and Y-axis represents
proportion of taxa. B) A timeline of weighted UniFrac distances (Y-axis) plotted by study visit
(X-axis) for individual subjects. Blue lines indicate the fungal wuf distances and the red lines the
bacterial wuf distances over time for each subject.
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Figure S4
Shannon Diversity Index for subjects administered an antibiotic (n=31) during the course of the
study or experienced a complication (n=30) A) All subjects who received an antibiotic at least
once during the study period or not at all. B) Shannon Index for samples obtained before, during
or following antibiotic administration. C) Shannon Index for visits a complication occurred or did
not occur. D) Shannon Index for samples corresponding to different antibiotic classes. Adjusted
(Holm) P-values were calculated by pairwise Wilcoxon rank sum test.
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Figure S5
Dendogram and heatmap illustrating positive (blue) and negative (red) correlations between the
taxa found in >1% abundance across the entire sample set and the pathogens and allergens
groups. Correlations were calculated by the Spearman correlation coefficient. Allergens and
pathogens groups are indicated with pink or blue bar, respectively, at the top of the heatmap.

89

Figure S6
Dendogram and heatmap illustrating positive (pink) and negative (blue) correlations between the
fungal and bacterial taxa found in >1% abundance across the entire sample set. Correlations were
calculated by the Spearman correlation coefficient. Significant correlations are marked with an
asterisk (p<0.05).
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Figure S7
Quantitative culture data. A) Quantitative counts for C. albicans and C. freundii planktonic and
biofilm populations growing as mono-culture (m) or co-culture (cc). B) Quantitative counts for T.
asahii and S. simulans planktonic and biofilm populations growing as mono-culture (m) or coculture (cc). All biofilm counts were obtained after washing the biofilms 2 x 1 mL of sterile
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water. Counts are averaged across a minimum of two replicates and two serial dilutions per
replicate.
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1633

Tables
Table 1: Subject Demographics and wound
characteristics
3.12
Tables
n

1634
1635
1636
1637
1638
1639

Subjects

100

Samples

384

Sex (M/F)

78/22

Type 2 Diabetes

87

Ulcer Duration (wks), mean (SD)

33.1 (41.6)

Ulcer Location

1640

Forefoot

73

1641

MidFoot

20

1642

Heel

7

1643

End of Study Reason

1644
1645

Healed

75

Unhealed

5

Amputation

7

Other Infection

3

Dropped Study

10

Subjects with detected ITS1

79

Samples with detected ITS1

275

Table 1
Subject Demographics and wound characteristics
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Table 2: Distribution of top 1% identified fungal taxa
Fungal Taxa

% Samples

No. Patients

Cladosporium herbarum

41

56

Candida albicans

22

47

Unclassified Ascomycota

16

36

Family Nectriaceae

16

41

Candida parapsilosis

15

37

Aspergillus cibarius

12

30

Epicoccum nigrum

9

27

Penicillium sp

9

26

Leptosphaerulina chartarum

7

23

Penicillium bialowiezense

6

19

Gibberella_zeae

6

18

Hypocreales sp

4

14

Order Capnodiales

4

15

Trichosporon asahii

10

24

Trichosporon sp

4

12

Rhodosporidium diobovatum

5

16

32

55

Ascomycota

Basidiomycota

Unclassified fungi

Table 2
Distribution of the top 1% identified fungal taxa.
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Table S1
Summary of Spearman correlation coefficients and p-values for supplementary figure 1.
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Taxa
Order Saccharomycetales
Mycosphaerellaceae sp.
Candida albicans
Tremellales sp.
Sporobolomyces ruberrimus
Phlebia radiata
Trichosporon sp.
Kluyveromyces marxianus
Antrodia xantha
Eurotiales sp.
Class Agaricomycetes
Candida xylopsoci
Ceriporia purpurea

p-value
0.024
0.492
2.19 E-05
0.0191
0.0191
0.0191
0.870
0.0191
0.0325
0.0226
0.0226
0.0191
0.0191

Table S2:
Differentially abundant taxa between forefoot and hindfoot wounds (p-values calculated by
analysis of variance and adjusted by the Benjamini & Hochberg method)
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CHAPTER 4 – Longitudinal study of the psoriasis-associated skin microbiome
during therapy with ustekinumab

The contents of this chapter are being prepared for submission as:
Michael Loesche, Joseph Horwinski, Amanda Tyldsley, Elizabeth A. Grice. Longitudinal
study of the psoriasis-associated skin microbiome during therapy with ustekinumab.

4.1 Abstract
Psoriasis is a chronic autoimmune disease primarily affecting the skin and joints, but may
have systemic inflammatory consequences. The worldwide prevalence of psoriasis may be as
high as 3%, though this varies by geography and ethnicity. The etiology of psoriasis is currently
unknown, but recent studies suggest that the microbiota of the skin may be involved. Despite this,
our understanding of the role of the cutaneous microbiota in psoriasis is lacking. Previous studies
have suggested that psoriatic lesions harbor a distinct microbiome compared to non-lesion skin,
however, these studies are limited by small sample size. Moreover, only one study has provided
longitudinal data. Here we present the results of a longitudinal study of the skin microbiome of
psoriasis and its response to ustekinumab therapy with 112 weeks of follow-up. We sampled the
microbiota of 114 subjects at six body sites, including the arm, axilla, buttock, leg, scalp, and
trunk, at contralateral lesion and non-lesion sites. Differences detected between lesion and nonlesion skin at baseline, were mild and body-site specific. After 28 weeks of ustekinumab therapy,
specific taxonomic differences between lesion and non-lesion skin were no longer detectable.
This was accompanied by a marked increase in sample variance, paradoxically resulting in
increased dissimilarity between lesion and non-lesion skin. In addition, ustekinumab therapy
induced moderate shifts in community structure, including increases in atypical skin bacteria such
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as Propionibacterium species, which was shared by multiple body sites regardless of lesion
status. After week 28, a subset of subjects were deprived therapy until recurrence of their lesion,
after which they received a customized dosing frequency ranging from 12 to 24 weeks. After 112
weeks of follow-up, we noted no differences of the microbiome between subjects receiving
normal or tailored dosing frequencies. Our findings suggest that the effect of psoriasis lesions is
perhaps secondary to alterations in community immunity on the cutaneous microbiome. Together
our results confirm findings from previous studies, but also expand upon and provide nuance to
our understanding of the skin microbiota in psoriasis.

4.2 Background
Psoriasis vulgaris (“plaque” psoriasis) is a chronic, immune-mediated disease primarily
affecting the skin and joints, though an appreciation of its systemic effects is growing. Psoriasis
lesions are classically described as well-demarcated, erythematous plaques covered with a silver
scale, however, the severity and distribution of the plaques varies greatly (Nestle et al. 2009). The
global prevalence of psoriasis is between 2% and 3% (Perera et al. 2012), though it varies
globally, largely as a function of ethnicity and latitude, with higher rates in those of European
ancestry and northern latitudes (Parisi et al. 2013). The exact mechanism underlying the
pathogenesis of psoriasis remains unclear, though most models incorporate aberrant T cell and
keratinocyte responses in addition to a component of genetic susceptibility. Specifically, there is
a growing appreciation of the role of the innate immune system in psoriasis pathogenesis, as
inflammatory cytokines and cells associated with innate immunity are more prominent in
psoriasis (Sweeney et al. 2011).
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Because the innate immune system is the first line of defense against invading pathogens,
many have questioned whether there is a microbial component contributing to the pathogenesis of
psoriasis (Fry et al. 2013). There is a long-standing association between recent Group B
Streptococcal infections and exacerbations of psoriasis generally and in particular guttate
psoriasis subtype (Telfer et al. 1992; Leung et al. 1995; McFadden et al. 2009), however, antistreptococcal treatment does not seem to modify disease (Owen et al. 2000). The specific
association with streptococcal species led to the hypothesis that psoriasis may be an inappropriate
reaction to other bacteria colonizing the skin or even entire communities.

Inflammatory bowel disease (IBD; ulcerative colitis and Crohn’s disease) is also
immune-mediated and clearly associated with microbial dysbiosis in the gut (Kostic et al. 2014).
Interestingly, the incidence of psoriasis is nearly five times higher in patients with Crohn’s
disease and their immediate family (Lee et al. 1990), suggesting a systemic pathological
commonality. Comparing the genetics of psoriasis and IBD also reveals recurring themes,
implicating a multitude genes associated with the immune system, specifically the Th1 and Th17
axes (Lees et al. 2011). Because clues to the pathogenesis of disease are often revealed in other
diseases that similarly behave or overlap epidemiologically, we hypothesize that understanding
the skin microbiota of patients with psoriasis is critical to understanding its underlying
pathogenesis.

Our understanding of the skin microbiota in psoriasis is in its infancy. Previous studies
have consistently identified differences between healthy control skin and psoriatic plaques;
however, the specific differences identified have not always been consistent. Moreover, these
early studies varied in sample type and sequencing methodology(Gao et al. 2008; Fahlén et al.
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2012; Alekseyenko et al. 2013). Notwithstanding these differences, some trends have emerged.
Compared to healthy skin, psoriasis lesions trend towards lower Actinobacteria and
Propionibacterium levels (Gao et al. 2008; Fahlén et al. 2012). A later study by Alekseyenko et
al also found decreased microbial diversity, decreases in the aggregate composition of common
skin commensals such as Corynebacterium, Propionibacterium, Streptococcus, and
Staphylococcus, and increased sample variance in psoriatic subjects versus healthy controls
(Alekseyenko et al. 2013). Interestingly, even the unaffected skin of psoriasis subjects is
qualitatively different from healthy skin, though less so than lesion skin, as demonstrated by the
ability of machine learning algorithms to accurately classify skin microbiome samples (Statnikov
et al. 2013).

In the present study, we address several important limitations of previous studies, which
have largely aggregated samples from various anatomical skin sites, ignoring the
microenvironment specificity of the skin microbiome (Grice et al. 2009) and potential for sitespecific trends. In addition, little is known of the longitudinal dynamics of the skin microbiota in
response to systemic therapy. Alekseyenko et al followed 17 subjects for 36 weeks of treatment,
but did not detect any significant changes from baseline (Alekseyenko et al. 2013). However,
subjects in this study received a variety of treatments, complicating direct comparisons, further
compounded by the naturally high variance of the skin microbiota (Grice et al. 2009). Moreover,
this and all previous ones were limited by small sample sizes, which limits the ability to detect
subtle differences.

Here we present the results of a longitudinal study where 114 subjects received
standardized therapy for their plaque psoriasis with up to 112 weeks of follow up. We present
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evidence that confirms findings from previous studies, but also expands upon and provides
nuance to our understanding of the skin microbiota in psoriasis. We reveal the body-site specific
effects of psoriasis on the skin, with samples across 6 body sites for all subjects. We characterize
the response of the skin microbiome to ustekinumab, a biologic therapy targeting IL-12 and IL23, over 112 weeks of follow-up. Finally, we reveal the effect of lesion recurrence and “subjecttailored” dosing frequencies on the skin microbiota.

4.3 Results: Phase I – Response to Ustekinumab
4.3.1 Characterization of subject demographics and summary of study design
114 subjects with psoriasis vulgaris (“plaque” psoriasis) were enrolled into a sub-study to
examine skin microbiome changes with ustekinumab treatment. The sub-study was part of a
longitudinal study to explore alternative dosing regimens for ustekinumab treatment. The study is
divided into two phases (Fig 1, see Methods: Study Design). In Phase I, subjects received 28
weeks of standardized treatment with ustekinumab. In Phase II, after 28 weeks of standardized
therapy, subjects achieving a therapeutic response (PGA < 2) were randomized to either a
standard maintenance regimen of weight-based dosing every 12 weeks (Group 1) or a “subject
tailored” off-label dosage regimen (Group 2) (Fig S1 and S2). The results of the randomization
process are summarized in Table 1. Twenty-five subjects failed to achieve a therapeutic response
to therapy and were dropped from the study for Phase II analysis. Those that did not achieve PGA
< 2 had significantly higher psoriasis severity scores at enrollment and baseline sampling of their
microbiota, as measured by the PASI metric and the proportion of body surface area (BSA)
affected. Additionally, a greater proportion of those subjects randomized (Groups 1 and 2) were
white when compared to the non-randomized group (Table 1).
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4.3.2 Skin microbiome differences between lesion and non-lesion skin are mild
and site specific.
We investigated the effect of psoriatic plaques on the composition of the skin microbiota
at baseline for each of six body sites including the arm, axilla, buttock, leg, scalp, and trunk.
These sites were selected for their predilection for lesions in psoriasis vulgaris. Furthermore,
since it has previously been demonstrated that the skin microbiome drastically differs by body
sites (REF), we performed all analyses in a site-specific manner, comparing plaque microbiota to
that found on the contralateral unaffected site of the same subject (“control”). For the purpose of
these analyses, Group 1, Group 2, and non-randomized subjects were included. We first
compared relative abundance of taxa at the species level or the highest level of taxonomic
classification achieved. Overall, clear and plaque sites were remarkably similar, though some
body-site specific differences were detected (Fig 2A). In leg lesions, we detected decreases in the
relative abundances of both Caulobacteraceae and Corynebacterium as compared to control leg
sites (P < 0.05). In scalp lesions, we found an increase in Bacilli and decrease in
Propionibacterium acnes relative abundance (P < 0.05) compared to control sites. At the phylum
level, the leg, scalp, and trunk had higher levels of Actinobacteria in the lesions, while Firmicutes
was significantly lower in the scalp and trunk lesions (P < 0.05) compared to their respective
unaffected control sites.

We also identified body-site specific differences in microbial diversity between psoriatic
lesions and non-affected skin (Fig 2B). The buttock, scalp, and trunk all exhibited increased OTU
richness in the lesion skin (P < 0.05) while the scalp and trunk also had higher Shannon diversity
levels in lesion skin, indicating greater evenness in the microbiota (P < 0.05). The psoriatic
lesions of the trunk had higher levels of phylogenetic diversity than the normal skin (P < 0.05).
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The trunk demonstrated the most consistent results with all three diversity metrics indicating that
lesion sites were more diverse than control non-lesion sites.

Though we detected differences between the lesion and non-lesion skin at certain body
sites, we wondered if there were less obvious patterns differentiating the two. We implemented a
machine-learning approach to determine whether more subtle patterns of variation in the skin
microbiome distinguish lesion from non-lesion sites at the baseline visit. For each body site, a
random forest model was trained to identify psoriatic-lesion samples using exclusively OTU
relative abundances. The models’ accuracy ranged from 60.5-87.8%. In the case of the arm,
buttock, and trunk, the classification accuracy was significantly better than chance (Table 2).
Attempts to accurately classify lesion and non-lesion skin failed at subsequent time points in the
study, indicating that differences between lesion and unaffected skin were strongest at baseline
prior to treatment. The classification capacities of our models are similar to or in some cases
surpasses what has been reported in previous studies (Statnikov et al. 2013). This is likely due to
the increased sample size and site specificity of the training data.

4.3.3 Lesion and non-lesion skin microbiota respond similarly to ustekinumab
therapy
We next investigated how the microbiota of lesion and non-lesion sites changed as a
result of the systemic therapy with ustekinumab. We compared the relative abundances of the
major taxa over time at each body site, analyzing lesion and non-lesion control sites separately.
We detected significant changes in 11 major taxa in at least one body site (Kruskal-Wallis test; P
< 0.05, FDR adjusted), the majority of which were shared across more than one body site (Fig
3A). Relative levels of Agrobacterium, Bradyrhizobiaceae, Caulobacteraceae, and Pseudomonas,
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exhibited increases in their relative abundance in at least five of the six body sites (Fig 3B).
Staphylococcus and S. epidermidis displayed slight decreases in four and five body sites,
respectively. Acinetobacter, Bacilli, Gemellales, Peptoniphilus, and P. acnes demonstrated more
body-site specific patterns. The lesion and non-lesion sites experienced similar changes, sharing
22 of the 41 total findings of differential relative abundance. Surprisingly, there were more
changes in bacterial taxa in the non-lesion sites than the lesion sites, 14 and 5 respectively (Fig
3B).

Because the control non-lesion sites experienced similar if not greater changes in specific
bacterial taxa than lesion sites with treatment, we further investigated how much each site
changed respective to its baseline microbiome. We accomplished this by calculating the weighted
UniFrac (wUF) distances between baseline samples and samples collected at subsequent study
visits. The wUF is a metric used to assess similarity between samples, which incorporates both
the abundance and phylogenetic relationships of microbial communities in the calculation
(Lozupone et al. 2010). Values of the wUF metric range from 0 to 1, with a score of 0 indicating
complete dissimilarity between the samples and a score of 1 indicating complete similarity of the
samples being compared. As expected, all body sites exhibited significant dissimilarity from their
baseline sample, which ranged from 0.24-0.39 at week 4 and 0.29-0.45 at week 28 (Fig. 4). The
leg and trunk both exhibited significantly higher rates of change in the lesion sites for the week 4
and week 28 time points (P < 0.05). Of the body sites, scalp remained the most stable in both
lesion and unaffected control sites. This may be a reflection of the highly sebaceous and haired
microenvironment exerting selective pressure on the microbial communities.
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4.3.4 Microbiota of lesion and non-lesion skin diverges with treatment
We next evaluated whether differences between lesion and non-lesion skin dissipated
with ustekinumab therapy. We first tested the persistence of the taxa that were differentially
abundant at baseline (identified above). The baseline differences were no longer detectable by
week 28, however, different taxa were identified at later time points that differed in lesion and
non-lesion skin (Fig. 3C). For the scalp, there were higher levels of Finegoldia, Gemellales,
Staphylococcus, and S. epidermidis in lesion compared to non-lesion skin at week 4. Lesions in
the arm had higher levels of S. epidermidis and lower levels of Pseudomonas at week 28. The
trunk demonstrated higher levels of Streptococcus in lesion skin at week 28. Moreover, there
were no detectable differences in microbial diversity by week 28, with the exception of the trunk
where the lesion sites were more diverse than the non-lesion sites (P < 0.05). This led us to
conclude that lesion and non-lesion sites were becoming more similar with treatment.

We then evaluated whether the microbial communities from lesion and non-lesion skin
had indeed converged with ustekinumab treatment. We used the weighted UniFrac (wUF)
dissimilarity metric to generate pairwise-distances between lesion and non-lesion samples.
Paradoxically, all body sites exhibited similar trends towards divergence as treatment progresses,
with the exception of the scalp (Fig 5). This trend was significant in the case of the arm, buttock,
and leg (P < 0.05). This finding appeared to directly contradict our previous results above.
However, these are not mutually exclusive findings as a simultaneous increase in community
variance and a resolution of differential selective pressures would yield similar results. The scalp
proved to be the exception to general trend, showing significantly less divergence between lesion
and non-lesion skin than the arm, buttock, and trunk sites (P < 0.05). As discussed before, this
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may be due to the presence of hair and sebum on the scalp exerting stronger selective pressures
on the microbiota than the effect of lesion or treatment.

4.3.5 Greater heterogeneity within psoriatic lesions than non-lesion skin
We hypothesized that psoriasis lesions may disrupt mechanisms maintaining body-site
specific microenvironments, such as sebum or sweat production. To test this, we assessed intersubject heterogeneity of lesion and non-lesion skin for each body site. We calculated the wUF
distance between samples from different subjects at the same body site. At the baseline visit, we
found that there was greater heterogeneity in lesion skin compared to non-lesion skin across all
body sites except the axilla (P < 0.05, Fig 6A). With the exception of the arm, this pattern was
maintained until week 28, though the magnitude of the difference diminished likely as a result of
lesion improvement. Interestingly, as subjects’ treatment continues, intra-group heterogeneity
continues to increase in all body sites, again indicating that ustekinumab treatment affects the
skin microbiota systemically.

We next investigated whether body site niches became more distinct when compared to
other body sites. We calculated the mean distance between body sites per subject via the wUF, as
a measure of body site dispersion. At all time points, the non-lesion sites exhibited greater
dispersion than the lesion sites (P < 0.05), though this was not significant during the baseline visit
(Fig. 6B). However, both lesion and non-lesion body sites became more distinct with treatment,
perhaps an indication that psoriasis impacts skin in ways that are subtler than plaques
development. Interestingly, the lesion and non-lesion sites did not converge with therapy,
possibly suggesting that the prior presence of a plaque has lasting effects. Together, these results
suggest that psoriasis lesions diminish the distinctiveness of body site niches.
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4.4 Results: Phase II – Duration of Ustekinumab Response
4.4.1 The skin microbiome is not predictive of the duration of therapeutic
response to ustekinumab
We assessed whether the skin microbiome was indicative of subjects’ duration of
response to ustekinumab. To do this, we compared multiple features of the skin microbiome
between subjects with different therapeutic response durations (12, 16, 20, and 24 weeks) during
the randomization visit (week 28). In general, there were no significant differences between these
groups in taxonomic composition, community diversity, or similarities between lesion and nonlesion sites. The exception was the non-lesion scalp, which exhibited higher levels of Shannon
diversity and OTU richness between the 16-week group and the 20-week groups for non-lesion
sites at baseline (data not shown). For the lesion sites, the scalp showed higher levels of Shannon
diversity between the 16-week group and the 24-week group during the 28-week time point.
However, it is unclear whether this is associated with the underlying biology or a result of noise
in a smaller sample set.

We then applied our machine learning approach, as before, to detect more subtle patterns
in the microbial composition. We focused on the extremes of the possible therapeutic durations,
12 and 24 weeks. We generated multiple models with three different classification tasks: 1) 12week group v. the rest, 2) 24-week group v. the rest, and 3) 12-week v. 24-week groups. This
method also failed to significantly distinguish the samples in all cases (data not shown). It should
be noted that this analysis is limited by our sample size, and true patterns may yet be found with
larger data sets.
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4.4.2 Recurrent lesions do not resemble original lesions
For subjects randomized to Group 2, the 28-week dose was withheld until their PGA
score reached or exceeded 2. This presented us an opportunity to determine if the skin microbiota
would return to their baseline state with recurrence of disease. We calculated the wUF distances
between the baseline visit (week 0) and both week-28 and recurrence visits. We did not detect
any differences between the two time points (Fig 7), nor did we find any difference between the
lesion and non-lesion skin. This may be further evidence of the non-specific effects of psoriasis
lesions on the skin microbiota. Alternatively, ustekinumab may have more subtle effects on the
skin microbiota than the formation of skin lesions.

4.4.3 No difference between standard and tailored dosing on effect of skin
microbiome
A final sample was collected at week 112, at which point subjects had been on their
dosing regimen for at least 70 weeks. We investigated whether different dosing regimens would
impact the skin microbiota. We first compared the taxonomic composition of each group for both
lesion and non-lesion skin sites. There were no differences detected between the study groups,
and this was true of both lesion and non-lesion sites. We also did not find any differences in
microbial diversity as measured by OTU richness, Shannon diversity, or phylogenetic diversity.
We then used the wUF distances to examine associations between the skin microbiota and their
respective treatment group and lesion status (Fig. 8). We tested for non-random clustering in
these groups via body-site specific ADONIS models, which incorporated terms for lesion status
and treatment group. We did not detect any differences for either term in any body site. These
results suggest that the dosing regimen does not significantly affect the composition or diversity
of microbial communities on the skin.
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4.5 Discussion
One of the challenges of the presented study is its sheer scale. Our data set includes
samples from 114 subjects, five time points, and up to 12 sites per patient per time point, yielding
over 4,700 possible samples. We endeavored to provide a comprehensive analysis of the skin
microbiome in psoriatic patients, how it evolves with treatment, and how it responds to treatment
withdrawal in a body-site specific manner. We built on the foundational work of previous reports
and attempted to expand upon and contribute nuance to our understanding of the microbiome and
its interactions with psoriasis.

We found that psoriatic lesions exhibited a modified skin microbiome at the baseline
study visit, before treatment had commenced. In line with previous studies, the effect of psoriasis
lesions on the microbial composition and structure was relatively minor. Even so, the changes
identified were specific to the body site, with no bacterial taxa being differentially abundant
across more than one body site. Previous work has not commented on differences between body
sites. The work presented here represents a significant advancement in our understanding of the
psoriasis microbiome and importantly, should inform future study designs.

Though we did not have a healthy control group for comparison, we noted an overall
lower abundance of Propionibacterium and Staphylococcus and increased Corynebacterium in
lesional skin compared to the healthy skin microbiome reported in Meisel et al, a study from our
group that employed the exact same sample collection, processing, and sequencing methodology
(Meisel et al. 2016). Moreover, the combined proportion of rare taxa (<1% abundance) made up a
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larger fraction of the psoriasis-associated microbial communities than is typical for skin samples.
This suggests that the skin of patients with psoriasis is less hospitable to typical skin bacteria,
instead being colonized or contaminated by generally rare environmental bacteria.

Unlike the skin disorder atopic dermatitis which has been studied extensively with regard
to the skin microbiome and is consistently associated with large increases in S. aureus and
parallel decreases in microbial diversity(Kong et al. 2012), there is little consensus on the specific
bacterial taxa or diversity measures that define psoriasis. This could be a consequence of the
diversity of sampling and sequencing methodologies implemented by the various studies,
however, it could also be an artifact of the highly variable skin microbiota. Alternatively,
psoriatic lesions may have minimal consequences on the microbiota of the skin. Because of the
low bioburden of bacteria on human skin and the high exposure to environmental contaminants,
the true effect of psoriasis on the skin microbiome may elude even a large study such as ours. A
large focus of the work presented here is on exploring the level of heterogeneity in the skin
microbiome of psoriasis, which furthers observations first made by Alekseyenko et al
(Alekseyenko et al. 2013) in psoriasis and our own work on healthy skin (Grice et al. 2009).
Lesion and non-lesion samples from the same subject were more similar to each other than either
was to the same site in other subjects, which was true even after successful treatment. That is to
say that unaffected skin has more in common with affected skin from the same subject than it has
with unaffected skin in other subjects. This observation is simultaneously a possible explanation
for the discrepancy of previous findings and a hurdle that future studies will need to grapple with
when trying to delineate the effects of psoriasis versus the environment.
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In the first phase of our study, we characterized the microbiome shifts secondary to a
standardized treatment with ustekinumab. Only one study has explored the effect of systemic
therapy for psoriasis in a longitudinal setting, though it was limited in sample size and surveyed a
wide range of drugs including ustekinumab. The study presented here expands upon it in sample
size, but also narrows the focus to ustekinumab. The focus on a single agent reduces the expected
variance due to the administered drug; however, it does limit our ability to generalize our findings
beyond ustekinumab.

The differences we identified at baseline had all dissipated by the 28th week of treatment,
however, other differences emerged transiently and as before were body-site specific. When we
quantified the divergence between lesion and non-lesion sites, we found, unexpectedly, that the
treatment increased the level of divergence between the two sites. This was an unexpected
finding, as one would expect lesion and non-lesion sites to converge as the plaques dissipated.
Moreover, the mean variance between samples from the same body site increased with treatment,
for both lesion and non-lesion skin. This argues for the existence of some “constraining” factor of
psoriasis that limits the variance seen systemically, which is relieved by therapy. A possible
explanation for the “constraining” factor is the increased production of antimicrobial peptides in
psoriasis, which may provide a strong selective pressure on the microbiota limiting its
composition to resistant bacteria. Alternatively, this may be due to behavioral differences, such as
scratching or the application of lotions and ointments that may homogenize the skin microbiota
within a subject.

We noted that as treatment progressed, the distinction between body sites increased, as
measured by their mean wUF distance. Psoriatic lesions are known to impair certain homeostatic
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functions of the skin, such as sweat production (Cormia and Kuykendall 1955; Johnson and
Shuster 1969; Rittié et al. 2016). This may hamper the ability of the skin to create distinct
microenvironments, leading to greater similarity between body sites. As treatment progresses and
lesions regress, these structures will begin to function more normally and perhaps increase the
specificity of body-site niches. It has been documented that these functions return to normal
gradually, over the course of at least three months (Suskind 1954), which fits in with the timeline
of our findings. Interestingly, lesion sites appeared to have a delayed response to the therapy,
which suggests that psoriasis lesions may have lasting effects on the microbiota that are longer
lived than deficiencies in sweat production.

A recurring theme was the similar trends detected in lesion and non-lesion skin, perhaps
indicating that unaffected skin is not necessarily physiologically normal. When we assayed the
longitudinal changes in microbiome composition, we noted that the vast majority of findings were
shared between the two. One hypothesis to explain the similarity is the systemic effect of
psoriasis. Alternatively, it may be that ustekinumab impacts the skin’s microenvironments
beyond the amelioration of psoriasis lesions. Regardless, it is interesting to note that ustekinumab
treatment broadly affected the skin microbiota beyond lesion sites.

During the second phase of the trial, subjects in Group 2 had therapy withheld until the
recurrence of their skin lesions. Interestingly, the recurrence was not associated with a return to
the microbiota of the baseline time point. This could be due to the relatively low lesion-scores
(PGA > 2) that were used for thresholds or the proximity to ustekinumab dosing. Alternatively,
this may be further evidence of the lack of a psoriasis-specific microbiome. We also compared
the microbial responses of subjects receiving the standard dosing frequency (Group 1) or the
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“tailored” frequency (Group 2). Notably, the skin microbiome was not remarkably different
between the groups. Subjects receiving the prolonged 24-week dosing frequency would
necessarily have less active drug in their system than those receiving the 12-week frequency, yet
we found no differences between these groups. This suggests that the effect of ustekinumab on
the skin microbiota has more to do with modulation of their skin phenotype than off-target effects
of the drug on the skin microbes.

4.6 Conclusions
Several attempts have been made to characterize the effects of psoriasis on the microbiota
of the skin (Fahlén et al. 2012; Alekseyenko et al. 2013; Statnikov et al. 2013; Takemoto et al.
2014; Martin et al. 2015; Drago et al. 2016), though there is little consensus between these
studies. Undoubtedly, some fraction of the inconsistency between studies is due to
methodological differences in sample collection techniques (skin biopsies, scrapings, swabs),
sequencing technologies (Sanger, 454-pyrosequencing, Illumina), and sample size. There is also
considerable variation in which and how many body sites were sampled. Moreover, those studies
that incorporated multiple body sites provided little if any analyses on the distinction between
sites in their analysis. However, where all previous studies agree is that the effect they notice is
small. Our results further this line of evidence and expand upon in several important ways.

We demonstrate that the impact on the skin microbiome is body-site specific. This is
important in interpreting the results from previous papers that made no distinction, but also will
be important to consider in future study designs. We also reaffirm previous studies’ findings that
the differences in the skin microbiome elicited by psoriasis lesions are small. However, we also
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present evidence that may explain the difficulty in differentiating the two. We show that lesions
have higher variance between subjects than non-lesion skin at baseline, confirming previous
findings (Alekseyenko et al. 2013). This suggests that the effect of psoriatic lesions on the skin
may be loosening normal selective pressures, rather than selecting for a different community
type. Thus, special care must be applied when identifying differentially abundant bacterial
species, so that they aren’t confused with stochastic fluctuations.

The skin microbiome was broadly affected by the systemic administration of
ustekinumab in both lesion and non-lesion skin. Moreover, lesion status was not associated with
the extent of change experienced by the skin. This suggests that the effect of ustekinumab therapy
is not limited to amelioration of plaques, but may alter the host-microbiota interactions across all
skin sites. Ustekinumab is likely affecting the microbiota indirectly via modulation of
inflammation rather than directly through off-target antibody interactions with the microbiota, as
dosing frequency did not impact the composition of the skin microbiome.

Our study reaffirms and builds upon previous understandings of the skin microbiome and
its interaction with psoriasis in several key areas. Our work is distinguished from previous studies
in the scale, attention to body-site specific trends, standardized treatment, and the duration of
follow-up. Our cohort nearly doubles the size of the previously largest study, and includes a
comprehensive analysis of body-site specific patterns. In contrast to previous longitudinal studies
with multiple treatments and only 36 weeks of follow-up, our subjects received the same
treatment and were followed for up to 112 weeks. Our results should inform future study design
and may have medically relevant implications for diagnostics and therapeutics involving the skin
microbiome.
124

4.7 Methods
4.7.1 Study Design
Subjects enrolled in the study were free of treatment, systemic or topical, for at least 4 weeks
(depending on drug class) prior to beginning the study. Subjects were instructed to withhold
showering, bathing, and using swimming pools or using topical emollients, soaps, shampoos,
deodorants or other treatments and products for a full 24 hours prior to sampling of skin
microbiota.

Phase I: The first phase follows subjects’ response to ustekinumab therapy over the course of
28 weeks. Subjects received ustekinumab doses at the baseline visit, after 4 weeks, and
subsequently in 12-week intervals. Microbiome samples were taken at weeks 0, 4, and 28 at six
body sites including the arm, axilla, buttock, leg, scalp, and trunk. Skin swabs were collected in
an area clear of lesions and if possible a contralateral site affected by a plaque. At the 28-week
time point, those achieving a therapeutic response (PGA < 2) were entered into the Phase II.

Phase II: During the second phase, one third of subjects were randomized to either Group 1
or Group 2. Group 1 received their next ustekinumab dose in accordance with the usual 12-week
dosing regimen. Subjects in Group 2 received a “tailored therapy,” which entailed withholding
their next dose until their PGA score equaled or exceeded 2. We define the visit at which this
occurs as the “recurrence” visit. PGA scores were assessed in 4-week intervals at weeks 32, 36,
and 40, corresponding 16, 20, and 24 weeks since their last dose. Once a subject experienced a
recurrence of their psoriasis, they received their next dose of ustekinumab and subsequent doses
at the greatest 4-week interval for which they were asymptomatic (PGA < 2). Thus if a subject
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developed lesions at week 34 (18 weeks since their last dose), they would be prescribed a 16week regimen. If a subject’s psoriasis did not recur by week 40, they were prescribed a 24-week
regimen. Microbiome samples were collected at the “recurrence” time point. If a subject did not
develop symptoms by week 40 (24 weeks since last dose), they were prescribed a 24-week dosing
regimen. A final time point was collected at week-112 for all randomized subjects.

4.7.2 Sample Sequencing and Processing
Subjects were enrolled at one of 23 clinical sites. Skin swabs were collected at six body
sites (arm, axilla, buttock, leg, scalp, and trunk) at both lesion-free sites and contralateral lesion
sites, if available. Amplification of the 16S rRNA gene V1-V3 region was performed as
previously described (Meisel et al. 2016). Resulting amplicons were sequenced using the Illumina
MiSeq platform with paired-end 300 bp ‘V3’ chemistry. [Sequences were assembled,
demultiplexed, and filtered for quality via super secret Qi pipeline] resulting in 109,132,204
sequences, which were then processed with QIIME 1.9.0 (Caporaso et al. 2010).

Sequences were size filtered to be between 460 and 600 nucleotides, which resulted in
88,780,568 reads and a median of 13,120 reads per sample. Because of the size of the data set,
sequences were clustered into operational taxonomic units (OTU) with a modified open-reference
OTU picking method. The reference set was generated by randomly subsampling 1% of
sequences and performing de novo OTU picking using the UCLUST algorithm (Edgar 2010) with
a 97% sequence-similarity threshold. For each OTU, the most common sequence was selected as
its representative sequence. This representative set served as the reference for QIIME’s default
UCLUST, open-reference OTU picking script, parallel_pick_otus_uclust_ref.py. OTUs were
assigned taxonomy using the RDP classifier (Cole et al. 2013) with the Greengenes 97%
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sequence-similarity database (DeSantis et al. 2006). Singletons, OTUs with only one sequence,
were removed. OTU corresponding to Cyanobacteria, Delftia, or were otherwise unclassifiable
were removed as contaminants. The remaining 133,398 OTUs were kept for subsequent analyses.

Samples were then subsampled to 2,000 sequences per sample for estimation of alpha and
beta diversity metrics. Microbial diversity was estimated using the following alpha diversity
metrics: 1) number of observed OTUs (OTU richness); 2) Shannon diversity; and 3) Faith’s
phylogenetic diversity. Sample similarity was estimated using the weighted UniFrac (Lozupone et
al. 2010) beta diversity metric.

4.7.3 Data Analysis
All analyses were performed using the R statistical package (R Core Team 2016).
Comparisons of relative abundance, microbial diversity, or sample similarities were performed
using Wilcoxon or Kruskal-Wallis tests where appropriate. P-value adjustments for multiple
hypotheses testing were performed for the multiple taxonomic comparisons and testing between
multiple time points by the false discovery rate method. Adjusted P-values less than 0.05 were
considered significant. Calculation of NMDS coordinates and ADONIS testing for non-random
clustering was performed via the vegan package (Oksanen et al.). We used the randomForest
package (Liaw and Wiener 2002) in conjunction with Caret (Kuhn et al. 2016) to perform the
machine learning analyses. The training set was created by randomly sampling 80% of subjects;
the remaining 20% were reserved for testing. The number of OTUs was pruned by first removing
near-zero variance and highly correlated (rho > 0.7) OTUs. We then performed recursive feature
elimination (RFE) with subsets of OTU of 10, 25, 50, 100, and all OTUs combined to identify the
ideal number of features to include. The random forest parameter mtry was tuned over five
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iterations. Both RFE and parameter tuning was evaluated by optimizing the ROC score over 10fold cross-validation repeated three times. Classification accuracy greater than chance was tested
with a Bernoulli binomial test.
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4.9 Figures

PHASE I

PHASE II
Group 1 (n = 21): Maintenance Regimen
Wk 28: PGA < 2

All Subjects (n = 114):
Dose at Wks 0, 4, 16

R

Responders (PGA < 2)
randomized at week 28 into
two groups

q12wks

Group 2 (n = 68): ‘Patient Tailored’ Maintenance Regimen
Weeks 28 to 40
Dose Interval Determination

Wk 32 (n = 14): PGA ≥ 2

q12wks

Wk 36 (n = 18): PGA ≥ 2

0

4

16

28

32

36

q16wks

Wk 40 (n = 10): PGA ≥ 2

q20wks

Wk 40 (n = 23): PGA < 2

q24wks

40

Sample taken at first time
point where PGA > 2

Weeks

112

= Microbiome sample taken

Figure 1
Clinical trial design diagram. 114 subjects were enrolled and received standard treatment with
ustekinumab at weeks 0, 4, and 16. At week 28, subjects with therapeutic responses (PGA < 2)
were randomized to one of two treatment groups. Group 1 received a dose at week 28 and
subsequently every 12 weeks. Group 2 subjects did not receive their dose until their PGA score
had reached or exceeded 2, measured in 4-week intervals. The longest 4-week interval for which
subjects’ PGA score was less than 2 defined their subsequent dosing frequency; this constituted
their “tailored” regimen. Microbiome samples were taken at multiple time points, indicated by the
orange circles on the time line.
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Figure 2
The effect of the psoriatic lesions on the skin microbiota at baseline. A) Stacked bar plot
depicting the mean relative abundances of the most abundant taxa of both lesion and non-lesion
skin by body site. Colored boxes indicate the mean proportion of specific taxa contributing at
least 1% to all samples. Significant differences are denoted by body site labels in the legend –
arm (Ar), axilla (Ax), buttock (B), leg (L), scalp (S), and trunk (T). B) Facetted boxplot of
sample diversity for both lesion and non-lesion skin split by body site. Facets depict different
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alpha diversity metrics including phylogenetic diversity (top), OTU richness (middle), and
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Figure 3
Longitudinal changes in taxonomic composition following ustekinumab treatment. (A) Plot
shows the mean relative abundance for taxa identified as changing in at least one body site.
Lesion and non-lesion skin are represented by orange and blue dots, respectively. Error bars
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represent the standard error of the mean. (B) Results of Kruskal-Wallis test for longitudinal
changes in relative abundance levels for each of the major taxa by body site. Colored tiles
represent significant findings in the non-lesion site only (blue), lesion site only (orange), or both
sites (purple). (C) Results of paired-Wilcoxon testing differences between lesion and non-lesion
sites at week 0, 4, and 28. Yellow tiles represent significant findings.
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visits (week 4 and 28). Data is split by body site. Non-lesion skin is represented by the blue bars,
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bars depict the standard error of the mean. Bar shading correspond to time points - week 0
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Figure S2
Subject randomization and dose frequency customization. Flow chart demonstrating how subjects
were randomized and what steps were taken when choosing the ‘subject tailored’ dosing regimen.
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4.10 Tables
Group 1
Subjects
Age
BMI
PGA
PASI
BSA
% Female
% White
% Hispanic
% Smoking
% Diabetic
Sun
Exposure
Outdoor
Exposure

Group 2

Not
Randomized

21
47.43
29.65
3.22
17.05
25.24
0.38
0.81
0.1
0.71
0.1

Overall
68
44.09
31.5
3.52
18.25
20.47
0.32
0.96
0.13
0.44
0.1

q12w
14
46.71
35.83
3.74
22.36
25.79
0.36
0.93
0.29
0.43
0.14

q16w
18
41.83
32.25
3.54
20.05
21.19
0.28
0.94
0.11
0.44
0.11

q20w
10
44.2
28.8
3.57
15.19
20.2
0.2
1
0.1
0.5
0.1

q24w
23
43.74
28.85
3.44
15.96
17.54
0.43
0.96
0.04
0.39
0.09

1.86

1.99

1.79

1.94

2.1

1.96

1.96

2.33

2.29

2.29

2.22

2.2

2.3

2.2

Table 1
Characterization of subjects’ demographics and results of randomization process

140

25
43.88
29.1
3.48
24.94
34.44
0.28
0.64
0.16
0.44
0.04

W0

Accuracy

AUC

p-value

Significance

Arm

87.8%

0.895

8.30E-07

***

Axilla

70.8%

0.547

4.20E-01

Buttock

77.8%

0.773

2.69E-02

Leg

60.5%

0.675

1.43E-01

Scalp

56.4%

0.693

4.38E-01

Trunk

78.1%

0.868

3.79E-04

*

***

Table 2
Psoriatic lesion classification accuracy by body site at the baseline (wk 0) visit.
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CHAPTER 5 – Conclusions and Future Directions

5.1 Conclusions and Future Directions
The work presented in this thesis represents a significant advancement in our
understanding of the longitudinal dynamics of the cutaneous microbiota when afflicted by
disease. In our studies of chronic wounds, we demonstrate for the first time the intrinsically high
levels of microbial flux and their relations to outcomes. Chapter 2 explored the bacterial
component, revealing the inverse relationship between community stability and the rate of
healing. We also characterize the effects of multiple classes of antibiotics on the bacterial
communities colonizing the wound. In Chapter 3, we uncover the fungal contributions to wound
healing, their associations with co-resident bacteria, and their ability to form inter-kingdom,
cooperative biofilms. Chapter 4 presents the largest and longest longitudinal study of the psoriasis
microbiome, revealing how the cutaneous microbiota respond to therapy and lesion recurrence.
Together these studies expand upon the foundational work generated by cross-sectional studies
and provide a foundation for future longitudinal analyses of the cutaneous microbiome.

We modeled the temporal dynamics of the diabetic foot ulcer (DFU) microbiota using
discrete and continuous frameworks. The first approach presumed the presence of distinct
bacterial community types, with the potential to direct the clinical course of the ulcer. This idea
has been applied in many ecological analyses of microbial communities, and is an attractive
approach for several reasons. Sample clustering dramatically reduces the variance and
dimensionality of the data, making subsequent analyses more tractable. Clustering algorithms are
agnostic to preconceived biases and are capable of detecting patterns often too subtle and
complex for human observers. However, approaches to clustering differ in the importance
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assigned to various community parameters, such as the weighting of sample parameters, ideal
cluster sizes, and calculations for sample inclusion. Clustering results may differ between
approaches, and it is often impossible to validate the results; however, these approaches can be of
great utility in isolating a signal in noisy data. This was the case in our study, where our Markovchain analysis revealed the positive association between frequent transitions and healing rates.
Moreover, wounds that became entrenched in community types dominated by Stahylococcus
aureus and Streptococcus were more likely to experience a negative outcome.

To validate our results, we applied mixed-effect modeling of community stability, which
provided greater resolution than the discrete transitions of our Markov-chain analysis. This
confirmed our findings and revealed an inverse relationship with community stability and healing
rates, which was apparent even after the first visit. Unsurprisingly, antibiotics led to increased
dynamism in the wound. Together these results suggest that a stagnant wound microbiota is
harmful to healing, and may reflect the failure of the wounds defenses to repel infection. This has
significant clinical applications, as DFU do not exhibit the traditional signs of infection, making
diagnosis of infection difficult. Thus, microbial dynamics may offer additional guidance for
clinicians managing chronic wounds.

The fungal communities of the wound may also reflect and contribute to the healing
outcomes of chronic wounds. The work presented here is the first to perform metataxonomic
methodologies to understanding these interactions. The DFU mycobiota was striking for its
interpersonal variation and paradoxically low intra-sample diversity. Moreover, the mycobiota
exhibited high turnover of its constituents visit-to-visit, though the wound was still more similar
to itself over time than to other individuals at the same time. The high level of variance
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introduced significant challenges for the analysis and pattern detection. However, patterns
emerged once taxa were categorized as either pathogen or allergen. Wounds dominated by
pathogens were more likely to have high levels of necrotic tissue and have poor outcomes. We
also demonstrated the viability of Candida albicans and Citrobacter freudii, isolated from a
single wound, to form cooperative, inter-kingdom biofilms.

Our work on the chronic wound, from both the bacterial and fungal perspectives, has
demonstrated that microbial dynamics can provide predictive power for stratifying patients at
risk. These studies would be greatly augmented by the inclusion of metagenomic sequencing,
which would reveal the functional capacity of the wound microbiota. The need for such studies is
obviated when one considers the tremendous genetic heterogeneity even within members of the
same species (Lapierre & Gogarten 2009). The prevalence of specific genes, such as those
involved virulence or antibiotic resistance, may increase the predictive power of our models and
yield biologically meaningful insight. To this end, we are actively pursing whole metagenome
sequencing of the samples included in the presented studies.

Future studies should increase the frequency of sampling to provide greater temporal
resolution to the observed phenomenon. We measured the wound microbiota at 2-week sampling
intervals, a limitation introduced by the use of total contact casts for offloading therapy. For many
body sites, microbial communities tend to maintain relatively stable community structure over
time(Ding & Schloss 2014). In addition, microbes in chronic wounds form robust biofilms (James
et al. 2008), shielding its members from external perturbations. However, our 2-week sampling
frequency may be masking interesting shorter-term dynamics, as the majority of bacteria replicate
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on the order of minutes to hours. This may be particularly true of the community responses to
antibiotic perturbations.

Our work on the cutaneous microbiome represents the largest longitudinal study on the
topic, both by number of subjects involved and the duration of follow-up. Similar to previous
studies, we found psoriasis lesions to have mild consequences on the composition of the skin
microbiota, however, this effect was body-site specific. One of the strengths of our study was the
standardized medical intervention received by all subjects, which reduces the variance introduced
by multiple therapies. We identified shifts in various taxa following therapy, but it is impossible
to determine whether this is due to amelioration of the lesions or some other effect of
ustekinumab. As in previous studies of subjects with primary immunodeficiencies, ustekinumab
therapy appeared to make the skin more permissive of atypical skin bacteria, such as
Pseudomonas species (Oh et al. 2013). In addition, the distinctiveness of body sites increased
during the course of therapy, suggesting that the normal physiologic determinants of the skin
microbiota were reestablishing themselves.

As before, our understanding of the interactions between the skin microbiota and
psoriasis would be enhanced by the addition of metagenomic sequencing. Metagenomic studies
have demonstrated that the functional composition of the microbiome is markedly more
consistent than the taxonomic composition (Human Microbiome Project Consortium 2012), likely
a consequence of the redundancy of genes. In psoriasis, there may be many bacteria capable of
filling an ecological niche, opened up by the dysfunctional cutaneous immune system.
Metagenomic profiling may also reveal specific metabolic pathways or biosynthetic gene clusters
that are associated with the development of or severity of psoriatic lesions.
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There is a shortage of statistical frameworks available for researchers to model the
dynamics of microbial communities in longitudinal settings. Longitudinal microbiome studies are
plagued by few time points and irregular sampling frequencies, making pattern detection difficult.
Moreover, studies are often designed to capture the perturbation and recovery of the microbiota to
some environmental insult, which often do not follow linear assumptions. This is even more of an
issue when experiments are attempting to elucidate the effects of stochastic perturbations. To
combat these issues, researchers will often analyze their time points as discrete categories, rather
than use a true longitudinal model. Some of these issues may be remedied by the use of additive
models, but require more time points than most studies have available.

Previous attempts have been made to combine regression techniques with generalized
Lotka-Volterra equations (which model microbial dynamics as a function of competitive
interactions) to model microbiota responses to external perturbations (Stein et al. 2013). This
group went on to model the effects of stochastic antibiotic exposure on Clostridium difficile
infection in patients hospitalized for cancer treatment to great success (Buffie et al. 2014). They
identified specific bacterial species that reduced the risk of infection, due to metabolic pathways
involved in modifying bile acids. Lotak-Voltera dynamics are exquisitely sensitive to initial
conditions. Much like a double pendulum, the patterns appear random, though they obey specific
rules. There is evidence to suggest that ecological dynamics operate in a non-linear or chaotic
manner (Sugihara et al. 2012). This finding may lead to the inclusion of non-linear ecological
modeling to the field of microbiome research. Indeed, approaches have been developed to allow
the “stitching” together of short time-series to create the long timelines required for non-linear
modeling (Hsieh et al. 2008). Such approaches will need to be modified to handle the high151

dimensionality and the compositional nature of microbiome data, but may represent an attractive
solution to the challenges faced by those studying microbial dynamics.
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